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Abstract 
 
Proteins perform many biological functions and characterizing their role in the cellular 
environment is critical in understanding a protein’s role in disease. ‘Bottom-up’ liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) offers the most effective strategy for 
large-scale global analysis of highly complex protein mixtures, i.e., proteomics. However, LC-
MS/MS workflow strategies must be carefully adapted to maintain experimental reproducibility 
and overcome inherent limitations in detecting low abundance proteins in concentrated mixtures 
and labile posttranslational modifications (PTMs). This dissertation presents LC-MS/MS based 
analytical strategies for the direct detection and site-specific profiling of S-palmitoylated peptides, 
and for characterizing low abundance host cell proteins (HCPs) in purified biopharmaceutical 
drug substances (DS). 
Chapter 1 presents an introduction to quantitative LC-MS/MS-based protein analysis, 
including instrumentation and techniques relevant to the work presented in Chapters 2 and 3. 
Chapter 2 discusses S-palmitoylation, the reversible and dynamic modification of a 
cysteine sulfhydryl with a 16-carbon fatty acid. The dynamic cycling between a protein’s 
palmitoylated and depalmitoylated states regulates several intracellular events such as protein 
activity, localization, and protein-protein interactions. N-Ras, a well-known driver of many 
cancers, is S-palmitoylated near its C-terminus, and despite the therapeutic potential of targeting 
this modification, direct detection of this modified peptide by LC-MS/MS has not previously been 
xvii 
 
successful.  In fact, robust methods for direct LC-MS/MS-based analysis of S-palmitoylated 
proteins have been lacking.  We addressed this issue by developing an LC-MS/MS “bottom-up” 
workflow that mitigates sample processing issues associated with S-palmitoylation, including 
peptide solubility, stability, LC column retention, and MS/MS-based sequence analysis. We 
successfully applied this workflow to directly detect and annotate endogenous acylation sites on 
recombinant N-Ras.  
Chapter 3 discusses the adaptation of an LC-MS/MS workflow for HCP characterization 
in biopharmaceutical drug substances. HCPs are native proteins derived from a host organism 
used to express biotherapeutic proteins and may be co-purified with a drug substance as process 
related impurities. The presence of these impurities in drug formulations may present problems in 
product performance and affect the health of patients. Therefore, effective monitoring of HCP 
levels in drug substances is essential. Common procedures for quantifying HCP content are 
limited to immunocapture detection methods, but serious efforts are underway in developing LC-
MS/MS strategies for characterizing HCPs. Problematically, HCPs can be 106-fold less 
concentrated than the biotherapeutic protein in downstream products presenting a dynamic range 
challenge for electrospray ionization-MS. We developed a generalized, semi-automated, and 
plate-based hydrophilic interaction liquid chromatography (HILIC) fractionation workflow to 
deplete biotherapeutic protein from DS with limited sample-specific optimization. Our method is 
practical, quantitative, and demonstrates industry leading HCP detection sensitivity by LC-
MS/MS.  
Chapter 4 provides a concluding summary of the novel contributions of our work and the 
broader impact on the field of LC-MS/MS based protein analysis. The developed method for 
direct detection of palmitoylated peptides promises to expand analytical profiling capabilities of 
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an under-represented PTM. Furthermore, the demonstrated robustness and dynamic range 
improvements for HCP analysis show promise for assisting downstream process development of 
biotherapeutic drugs as part of an MS-based analytical platform.  
1 
 
 
 
Chapter 1 
Introduction 
 
1.1 Proteome Analysis 
 A proteome corresponds to the complex milieu of proteins in a cell or tissue under a 
given set of conditions. These proteins function to catalyze chemical reactions, transfer signals, 
associate with other proteins, and provide structural support within the cell. As an example, the 
human genome encodes approximately 20,000 genes which can be transcribed into 
approximately 100,000 transcripts after post-transcriptional processing, such as alternative 
splicing and mRNA editing (Figure 1.1) [1,2]. These transcripts are translated into amino acid 
sequences which are folded into distinct three-dimensional (3D) protein structures. Amino acids 
comprising a protein can be modified with distinct chemical moieties, or post-translational 
modifications (PTM), further increasing proteome complexity to more than 1 million potential 
variants in human cells. These PTMs alter the chemical and physical properties of proteins, 
having a significant impact on their activity and function. Similarly, changes in each protein’s 
activity or expression level can have a significant impact on cellular function. Therefore, directly 
studying the proteome is crucial in understanding cellular function and disease pathology.  
 Major challenges in proteomics, the study of the global expression of proteins in a cell or 
tissue, are the complexity of the mixture and the several order of magnitude abundance range 
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over which each protein is present. Strategies for detecting and quantifying proteins between 
experimental conditions minimally require a separation component and a detection component. 
An early example of a proteomics strategy involved two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE), developed in the 1970’s. This approach enabled researchers to 
separate and detect up to 1,000 distinct proteins from cells [3-5]. In these experiments, protein 
extracts are separated in two dimensions by isoelectric point and molecular weight, respectively. 
Each protein ideally occupies one spot in a two-dimensional gel and is visualized with protein 
binding dyes or radiography. This strategy demonstrated the ability to detect and measure the 
abundance of many proteins at once. However, there are some limitations to the method in that 
only highly abundant proteins were detectable, and protein identification remained challenging.  
 
 Protein identification could be achieved by using internal protein standards, mapping the 
radiolabeled proteins with images from previous experiments, using fluorescently labelled 
chemical tags and antibodies specific to proteins of interest [4-9]. After transferring the proteins 
to a polyvinylidene difluoride (PVDF) blotting membrane, Edman degradation could also be 
used to determine the N-terminal amino acid sequence of a protein. However, chemically 
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modified N-termini will not react with phenyl isothiocyanate, the chemical reactant responsible 
for the required degradation reaction, and sequence coverage is limited to ~30 amino acids due to 
steric hindrance inhibiting the kinetics of cyclic derivatization. [10-11]. Digestion of the proteins 
into their constituent peptides on the other hand, offers greater information for sequence 
identification, however the analytical complexity greatly increases and requires more powerful 
tools such as mass spectrometry. 
1.2 Mass Spectrometry-Based Proteomics 
  The underlying principle of mass spectrometry (MS) is the separation of gaseous ions in 
electric and/or magnetic fields based on their mass-to-charge (m/z) ratios. The introduction of 
electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI) in the late 
1980s for efficient ionization and volatilization of proteins opened up MS to high throughput, 
high sensitivity, label free protein analysis [18-23]. The parallel developments in high throughput 
genome sequencing allowed generation of databases containing all possible protein sequences 
for matching with MS data [50-53]. Because modern MS-based proteomic analysis typically 
involves liquid chromatography separation (see section 1.3), ESI is most suitable as ionization 
occurs directly from the liquid phase. In ESI, a protein solution is pumped through a needle with 
a few kV potential applied with respect to the entrance of the mass spectrometer. Due to the 
generated high electric field, solution-phase charged species accumulate at the tip of the needle, 
resulting in charged droplet ejection due to Coulomb destabilization. Solvent evaporation 
generates smaller droplets that split and further evaporate until gaseous protein ions are formed 
and enter the mass spectrometer. This technique is considered “soft” as it ionizes biomolecules 
without fragmenting them [21,22]. ESI typically imparts multiple charges on large biomolecules 
such as peptides and proteins in a statistical manner with higher charge states observed for larger 
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molecules.  Thus, protein signals are spread over multiple charges states, a characteristic that can 
be useful but also limits ESI-MS signal-to-noise ratios. Therefore, proteins are typically digested 
into proteolytic peptides for improved ionization.  
 The multiple charging inherent to ESI allows for efficient tandem MS (MS/MS), in which 
sequencing of peptide ions is achieved through gas-phase fragmentation. In an MS/MS 
experiment, a peptide precursor ion is selected based on its m/z ratio (e.g., with a quadruple mass 
filter) in MS1 and activated with some form of energy introduction, resulting in cleavages of 
backbone chemical bonds. The resulting MS2 spectrum is comprised of these peptide ion 
fragments, which can be cross-referenced with theoretical m/z values of possible fragment ions 
from genome-derived databases to identify the peptide. Ideally, backbone cleavage should occur 
at each possible inter-residue position; however, bioinformatics approaches allow high 
confidence peptide identification from partial sequence information [51-53].  
 The most common type of MS/MS activation is collision-induced dissociation (CID), 
which accelerates the peptide ions with a static or radiofrequency electric field to induce 
energetic collisions with a neutral gas, such as helium, nitrogen, or argon. The kinetic energy 
transferred from colliding with the gas raises the internal energy of the peptide ion and leads to 
fragmentation of the peptide backbone [24,25]. The “mobile proton model” (Figure 1.2) is the 
generally accepted mechanism for dissociation of peptide cations under collisional activation. 
This model postulates that, upon vibrational excitation, a proton of a cationic peptide will 
migrate to various, less basic, protonation sites, including the backbone amide bond. The 
carbonyl oxygen of the N-terminal, proximal peptide bond nucleophilically attacks the carbon 
center of the protonated amide bond forming a protonated oxazolone. This cyclic complex 
dissociates into a linear C-terminal fragment, and a cyclic N-terminal fragment (Figure 1.2).  
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Either or both fragments may carry charge (and thus be observable) depending on the charge 
state of the precursor peptide and the proton affinity of each fragment [25-30].  N- and C-
terminal fragment ions from the associated amide bond cleavage are termed b- and y-type ions, 
respectively (Figure 1.3). 
 
 Higher-energy collision induced dissociation (HCD), a CID variant, uses static field 
acceleration into a separate collision cell to fragment precursor ions, in contrast to ion trap-type 
CID which uses an increased RF amplitude within the trap. The use of a separate collision cell 
avoids loss of lower molecular mass fragments due to changes in the trap stability region upon 
the RF amplitude change. Retention of low m/z fragments is useful for detecting protein 
modifications and isobaric labels [31]. Additionally, HCD (also referred to as beam-type CID) 
shows complementary fragmentation compared with ion trap-type CID, e.g., a greater abundance 
of a-type ions, resulting from further fragmentation of b ions via CO loss. However, one 
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drawback to CID/HCD-induced fragmentation methods is that they often induce cleavage of 
peptide and protein PTMs, thus precluding direct determination of PTM sites.  
  
 In contrast, electron transfer dissociation (ETD) induces fragmentation by transferring 
electrons from a radical electron carrier, typically polycyclic aromatic compounds such as 
fluoranthene, to higher charge state cationic molecules, including peptides and whole proteins. 
ETD involves fragmentation of backbone N-Cα bonds in peptides/proteins, generating 
complementary c- and z-type fragment ions (Figure 1.3), rather than the b- and y-type fragment 
ions formed in CID/HCD methods. ETD is advantageous because it can retain labile PTMs 
[33,34].  
1.3 Liquid Chromatography- Mass Spectrometry for Proteomics 
 In a sample containing thousands of peptides, separation prior to MS is required to 
provide resolution between isobaric and isomeric species. In addition, ionization suppression, an 
inherent property of ESI, limits global peptide detection in complex samples. Analytes are 
competing for charge and surface space in rapidly vaporizing ESI droplets, with analyte 
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saturation at the droplet surface preventing ejection of gas phase ions from analytes further inside 
the droplets [24]. Therefore, it is important to limit the abundance and co-ionization of 
competing analytes in a sample. Coupling liquid chromatography (LC) in-line with mass 
spectrometry (LC-MS) offers a powerful solution. 
 
 The process of digesting protein samples into peptides, separating the peptides with LC, 
and analyzing the sample with inline ESI-MS/MS [35-37] is called “bottom-up” or “shotgun” 
proteomics. Generally, an LC-MS/MS “bottom-up” workflow (Figure 1.4) begins with the lysis 
of cells or tissues of interest followed by extraction of the host proteome and enzymatic 
cleavage, or digestion, of the proteins into their constituent peptides, typically less than 30 amino 
acids long. Protein digestion into similar sized peptides is also advantageous from an LC 
standpoint as intact proteins vary widely in size and physical properties and may therefore not all 
separate optimally under the same LC conditions.  
Peptide mixtures are typically separated over a narrow-bore capillary column (75-100 µm 
inner diameter) packed with a particulate resin (1-5 µm diameter) at flow rates ~200 nL/min, 
referred to as nanoflow (nano)-LC. Reverse phase (RP) resins are silica particles modified with 
hydrocarbon chains, with 18-carbon chains (C-18) being the most common. Peptides interact 
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with the hydrocarbon chains and partition out of the liquid mobile phase. Mobile phase 
composition is changed over the course of the separation in a gradient manner, with a pump 
gradually adding organic solvent (typically acetonitrile or methanol) to the column. As the 
percentage of the organic solvent surrounding the resin increases, peptides partition back into the 
mobile phase and elute off the column. The principle behind separation is that strongly 
interacting solutes (i.e., more hydrophobic ones) retain on the column longer, thus effectively 
separating solutes in the order of their hydrophobicity [38-40].  
 While high-performance liquid chromatography (HPLC) affords excellent resolution, the 
high complexity of proteomic samples still presents a significant challenge. In complex digests, 
numerous peptides may have similar hydrophobicities and co-elute during the experiment. In 
addition, the abundance of each protein in a sample varies widely and low abundance peptides 
are typically not selected for MS/MS as instrument duty cycle determines how many MS/MS 
spectra can be generated per time unit. To combat these issues, there are many enrichment 
strategies intended to reduce sample complexity. Most widely used is affinity capture which 
immobilizes proteins of interest on a resin before washing away uncaptured background proteins. 
Proteins can be targeted for enrichment through strategies such as immunoprecipitation, 
chemical modification, or genetic engineering to contain enrichment tags [40-43]. Captured 
proteins are released from the resin through chemical or enzymatic degradation of the linker, 
proteolytic digestion, or eluting through other means. However, these enrichment strategies 
require proteins to be modified or to contain a common epitope. In untargeted studies, or studies 
of native proteins, such enrichment strategies may not be suitable. Therefore, adding additional 
dimensions of LC separation can also be exploited to improve bottom-up proteomics. Alternative 
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separation strategies such as capillary zone electrophoresis (CZE) have also recently been shown 
to be effective [108-110].  
 Common strategies for multidimensional separation include prefractionation on a resin 
complementary to the one used for LC/MS, or inline two-dimensional liquid chromatography 
(MudPIT) [125]. Chromatographic techniques complementing RP LC include size exclusion 
chromatography (SEC, which separates by molecular weight), ion-exchange chromatography 
(IEX, which separates by ionic strength), and hydrophilic interaction liquid chromatography 
(HILIC, which separates by hydrophilic interaction with a polar stationary phase).  Pre-
fractionation has the effect of greatly reducing chromatographic complexity in LC/MS but also 
decreases experimental throughput substantially depending on the number of fractions collected. 
2D-LC-MS is an alternative to off-line fractionation and involves the sometimes-complicated 
addition of a second column to a traditional LC-MS setup. This strategy is limited by the 
compatibility of both columns with the mobile phase composition, and often requires plumbing 
of additional diverter valves to ensure that peptides are retained and that the columns are 
equilibrated [45-46]. The main advantage of 2D-LC-MS is improved detection limits and 
decreased sample loss. However, this strategy requires longer uninterrupted mass spectrometer 
operation.   
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1.4 Bioinformatics for LC/MS/MS-Based Proteomics 
 Modern academic and commercial software algorithms can process raw files of LC-
MS/MS data and produce statistically valid lists of protein and peptide identifications in just 
minutes (Figure 1.5). Online repositories, such as Uniprot [1], provide databases of all protein 
sequences in an organism, and in silico digests of a downloaded proteome are stored as 
theoretical peptide lists. From these peptide lists, MS2 spectra are generated in silico with 
predictable fragmentation patterns and are matched to raw MS2 scans to identify the precursor 
peptides [48,50]. Scores are assigned to spectral matches and the highest scored sequence is 
stored in a list of peptides. Protein identifications are inferred by matching sequenced peptides in 
the theoretical peptide list grouped into proteins [50]. Peptide sequences and protein groupings 
are validated by evaluating each match against all other matches in the experiment. For statistical 
modeling, false spectra are generated from a database of reversed protein sequences and added to 
the theoretical peak list. Spectral matches to these reverse sequences are false discoveries. 
Statistical modeling of distribution scores from all matches is used to determine the minimum 
confidence score for valid hits and further filtering to remove identifications scored lower than 
the top percentile of false discovery scores, the false discovery rate (FDR), is performed to 
ensure the validity of identification lists [51-53].  
1.5 Quantitative Proteomics 
 Mass spectrometry is not inherently quantitative and, thus, measuring protein abundance 
in LC-MS/MS experiments is a unique challenge. The detector measures the ion current 
throughout an analysis with the detector response being linearly proportionate to the number of 
ions within its dynamic range. This property is useful in quantitation where the relative intensity 
of a peak can be used to determine a change in abundance (i.e., relative quantitation). However, 
12 
 
the signal intensity produced per peptide depends on individual ionization efficiency, which 
varies based on the chemical environment and is subject to systematic error between experiments 
[54,57]. Thus, in the absence of a constant detector response, it is challenging to accurately 
measure a peptide’s abundance using only signal intensity. Two types of strategies commonly 
used to circumvent this issue are ‘labeling’ and ‘label-free’ methods. Labeling works by altering 
the stable heavy isotope content/distribution in peptides, which changes their mass/mass 
distribution but not their ionization efficiency.  Such labeling can be performed either via cell 
culture in standard/isotopically enriched media (stable isotope labeling of amino acids in cell 
culture (SILAC)) [126], by introducing “light” and “heavy” chemical tags, or tags with different 
isotope distribution designed to fragment easily during MS/MS. Labeled proteins from multiple 
experiments or conditions are mixed and enriched together for decreased experimental error. An 
early example of this strategy, developed in the late 1990’s, is isotope coded affinity tags (ICAT) 
that utilizes isotopically labeled/unlabeled tags to derivatize and enrich free cysteines [58]. 
However, because cysteine is a relatively rare amino acid, this strategy is not universally 
applicable. By contrast, SILAC can label virtually all proteins but is only compatible with cell 
culture experiments. Also, both ICAT and SILAC double the complexity of LC-MS spectra as 
each peptide will appear as two distinct m/z signal clusters with the added signals potentially 
overlapping with other peptides. Isotopic labeling methods are useful but require additional 
experimental steps with expensive reagents. Additionally, stable isotope labels need to be 
designed carefully to prevent systematic errors caused by dissimilar behavior. For example, 
hydrogen/deuterium substitution is known to affect the retention time of the labeled peptides, 
while 12C/13C substitution does not show such an effect [60]. Newer technologies are 
commercially available that circumvent these issues by utilizing MS cleavable isobaric reagents 
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to label the primary amines of peptides and proteins. Isobaric tags for relative and absolute 
quantification (iTRAQ) [128] and tandem mass tags (TMT) [127] facilitate quantitative analysis 
with reporter groups that are generated upon fragmentation in the mass spectrometer. The 
fragmentation of the attached tag generates a low molecular mass reporter ion that can be used to 
relatively quantify the peptides and the proteins from which they originated. These tags can be 
designed for analysis of up to 16-multiplexed samples in a single experiment. 
  Label-free methods for quantitation are often used when peptide modification is 
undesirable or the cost of labeling is prohibitive [61-63]. In label-free workflows, samples are 
analyzed separately, and every workflow needs to be optimized for reproducibility to reduce 
systematic error. In contrast to labelling methods, each peptide ion MS peak is integrated and 
used as a measure of quantity [64,65]. The “Hi-3”, or “Top-3,” method [66] can be used to 
approximate the concentration of proteins in a sample. This method integrates the MS peaks of 
the top three ionizing peptides from each positive protein identification, averages the three signal 
intensities, and calculates the stoichiometry relative to the top three ionizing peptides from an 
internal standard. The internal standard, usually a tryptic digest of a protein standard from a 
different host organism, is spiked into the sample at a known molar concentration prior to LC-
MS/MS analysis. Since the detected abundance of each peptide from a protein digest is 
influenced by workflow factors, such as digestion and ionization efficiency, measuring only the 
top three peptides reduces the risk for significant under-estimation that results from considering 
low intensity peptides in abundance calculations. Similarly, by averaging at least three peptides 
from each protein, the variability in detector response to peptide ions can be mitigated and a 
close approximation to absolute abundances can be more confidently made. 
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1.6 Approaches for Annotating Protein S-Palmitoylation 
 S-palmitoylation, here referred to as palmitoylation, is a reversible and dynamic post-
translational modification (PTM) that results from the thioesterification of palmitate, a saturated 
sixteen-carbon fatty acid, to a cysteine residue of a protein. Protein palmitoylation was first 
reported in 1979, the same year as the discovery of tyrosine phosphorylation [67-69]. Similar to 
protein phosphorylation, it was quickly realized that palmitoylation is essential for intracellular 
signaling, and it is also critical in regulating the function of the Ras family of GTPases, Src-
family kinases, G-proteins, and G-protein coupled receptors [70-72]. 
 
 The dynamic cycling between a protein’s palmitoylated and depalmitoylated states 
(Figure 1.6) regulates several intracellular events such as protein trafficking, spatial localization, 
Figure 1.6 Dynamic cycling of protein palmitoylation is regulated by protein 
acyltransferases (PATs) and acyl protein thioesterases (APTs). Permission for reuse 
requested Graphic credit: Martin et al. [78]. 
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membrane tethering, and the resultant cellular signaling and protein-protein interactions [70-76]. 
The potential for reversibility of the thioester bond, a labile and high-energy bond [76,77], 
between a palmitate group and a free cysteine residue is unique among the characterized lipid 
modifications. Importantly, it is this reversibility of palmitoylation that enables dynamic control 
of both spatial and temporal protein function [78-81]; however, the importance of palmitoylation 
has only recently gained significant attention.  
 This historical lack of investigational attention may be partly attributed to a shortage of 
robust strategies for directly profiling this non-polar, non-antigenic modification [81,82]. 
Palmitoylated peptides can be challenging to detect directly because the acyl-chain is highly non-
polar and lacks sufficient antigenicity, rendering traditional PTM-specific enrichment strategies 
such as immunocapture techniques impractical. Additionally, thioester bonds are labile and 
prone to hydrolysis under conditions present in many protein analysis workflows, further 
complicating quantitative analyses and the detection of low abundant species. 
 
Figure 1.7 Current S-palmitoylation detection methods A) The acyl-exchange method 
blocks free thiols, hydrolyzes the thioesters, and then labels or captures the resulting free 
thiols for visualization and/or enrichment. B) The “click chemistry” method 
metabolically labels palmitoylation sites with 17-ODYA and uses copper catalysis to 
bioorthoganally ligate labeled sites to N3-modified tags for visualization and/or 
enrichment. Permission for reuse requested. Graphic credit: Hernandez et al. [81]. 
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 Originally, the most direct way to monitor protein palmitoylation was through metabolic 
labelling with [3H]- palmitate, followed by lengthy exposure times ranging from days to weeks 
[67-69, 83]. Recent advances in chemical tagging and MS-based proteome-profiling techniques 
have greatly expanded databases, such as Swiss Palm [82], which catalogs reported 
palmitoylation sites, to include hundreds of putative targets for palmitoylation [84-92]. Common 
approaches to enriching for and profiling the palmitoylome involve affinity capture techniques 
such as acyl-biotin exchange (ABE) followed by fluorescent detection or resin assisted capture 
of S-acylation sites (acyl-RAC) [92,93]. ABE traditionally involves a three-step procedure 
(Figure 1.7(a), [81]) that includes: complete blocking of free thiols with N-ethylmaleimide 
(NEM), hydrolyzing all thioesters with hydroxylamine [76], and labeling free sulfhydryl groups 
with a fluorescent or biotinylated marker [86].  
 Another approach utilizes bioorthogonal chemical ligation, or “click chemistry” (Figure 
1.7B,) [94-97]. This strategy involves metabolically labeling cells with alkynyl-analogues of 
palmitic acid, such as 17-octadecynoic acid (17-ODYA) [78,91]. The labeled proteins are then 
subjected to copper catalysis with azide (N3-) containing detection markers, such as fluorescent 
tags or biotin, for enrichment and/or visualization. This approach has shown to be highly 
successful and proteomics analysis using metabolic labeling and enrichment of 17-ODYA 
labeled proteins was able to annotate more than 300 palmitoylated proteins in neuronal stem cells 
[78]. In contrast to ABE methods, the metabolic incorporation of 17-ODYA into cell cultures 
minimizes false positives generated by ABE protocols due to incomplete alkylation of free 
cysteines or capture of endogenous hydroxylamine-sensitive thioesters. There are limitations to 
this approach, however, and poor metabolic incorporation rates of the alkynyl-analogues, 
metabolic degradation of alkynyl-fatty acids, and aberrant labeling of the N-terminus by 17-
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ODYA have been reported. Considering its potential for off-site labeling, sites reported as 
labeled with this analogue need further validation experiments to confirm the site is natively 
palmitoylated. 
As novel approaches are developed the list of palmitoylated proteins continues to expand 
and the critical role of protein palmitoylation in the function of many membrane localized 
proteins is difficult to ignore. Therefore, in order to better understand the nature and extent of 
palmitoylation in biological systems, it is necessary to develop analytical strategies that can 
globally profile acylation, differentiate between types of acylation, localize palmitoylation sites, 
and quantitatively measure changes in protein palmitoylation under various conditions. 
1.7 Host-Cell Protein Characterization in Biopharmaceutical Drug Substances 
 Host cell proteins (HCP) are native proteins derived from a host organism used to express 
biotherapeutic proteins for drug substances (DS), such as therapeutic antibodies and fusion 
proteins [98,99]. HCPs may be unintentionally co-purified with a DS as process-related 
impurities and the presence of these impurities may present problems in drug performance 
through eliciting immune responses in patients or contributing to the instability of drug 
formulations [99-102]. Due to their potential to affect product safety and efficacy, the 
concentration of residual HCPs in a drug product is generally considered a critical quality 
attribute (CQA) [103-105]. The ICH, a council of pharmaceutical regulatory bodies, defines a 
CQA as “a physical, chemical, biological or microbiological property or characteristic that 
should be within an appropriate limit, range, or distribution to ensure the desired product quality” 
[105]. Additionally, it is a US federal regulatory requirement to monitor the removal of HCPs in 
drug product during bioprocess development. Therefore, measuring HCP levels is essential 
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throughout manufacturing process development and at release testing to ensure adequate removal 
of these impurities [106,107].  
 
Multiple purification steps (Figure 1.8) ensure that residual HCPs are typically at very 
low levels relative to the therapeutic protein, often 100 parts per million (ppm) or less 
[106,122,123]. While these low levels are desirable, they present an analytical challenge for HCP 
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identification and quantitation. Enzyme-linked immunosorbent assay (ELISA) is currently the 
most common HCP analysis technique in industry as such assays offer high sensitivity, 
parallelizability, and quantitation of HCP content making them useful for support of routine 
analyses and process development [98,99,108]. Generic ELISAs for HCPs are typically created 
using polyclonal antibodies raised against antigen HCPs produced in culture from a process-
representative null host cell line. However, it remains challenging to achieve complete antibody 
coverage of all possible HCP species present in a cell line, and due to the fact that not every HCP 
is immunogenic, even the best process-specific HCP ELISA cannot detect 100% of possible 
HCPs [107]. Furthermore, detection sensitivity may vary for specific HCPs depending on their 
respective immunogenicity, resulting in dilutional nonlinearity and potentially an underestimate 
of residual HCPs [108].  
Orthogonal strategies have emerged with protein separation methods such as 1D and 2D 
sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE), 2D-differential in-gel 
electrophoresis (2D-DIGE), western blotting (WB), and capillary zone electrophoresis [108-
110]. However, each of these methods presents practical limitations, such as poor sensitivity 
and/or the inability to distinguish drug related fragments from HCPs.  
 LC-MS/MS-based “bottom-up” proteomics offers a highly sensitive, semi-quantitative 
method for HCP detection and identification which can be effectively used to support 
downstream purification process development [111,112]. Using a ‘bottom-up’ approach, HCPs 
can be identified by separating proteins or peptides with 1D or 2D-LC [113], analyzing peptides 
by MS/MS [114], and conducting database searches against the entire proteome of the host 
organism. Measurements of absolute HCP concentrations can be approximated with the ‘Top-3’ 
quantitation method [66]. This technique is less accurate than other approaches such as surrogate 
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peptide methods, but it is advantageous for proteomic-type HCP analyses since specific 
standards are not required for each analyte [113,114]. 
Biopharmaceutical product typically contains HCP concentrations less than 100 ppm (ng 
of HCP per mg biotherapeutic protein), which presents a dynamic range problem for ESI LC-
MS/MS analysis. Depletion of the biotherapeutic protein is necessary even when using state-of-
the-art mass spectrometers in order to lower dynamic range to detect HCPs at concentrations less 
than 10 ppm [114-117]. Adapting chromatography with long LC gradients and multiple 
separation dimensions such as 2D-LC [113] and/or ion mobility separation [114] to resolve the 
low abundance peptides from the digested DS has been an effective approach. However, these 
strategies involve complex instrument modifications, and decrease processing throughput which 
limits general practicality. Other approaches include depleting monoclonal antibody (Ab) with 
affinity purification [113-116]; however, HCPs that strongly interact or aggregate with the 
biotherapeutic protein may not be enriched without strong denaturing conditions, limiting 
potential enrichment options. Furthermore, affinity purification strategies require careful sample-
specific optimizations which are difficult to adapt into standardized protocols for downstream 
product analysis.  
 Another LC-MS/MS approach to enrich for residual HCPs, is to precipitate 
biotherapeutic Ab from a sample after overnight native trypsin digestion prior to analysis [117]. 
Developed at Eli Lilly, the principle hypothesis of this method is that the Ab in its rigid, folded 
structure will have a slower kinetic rate of digestion by trypsin than natively folded HCPs, and as 
a result, HCPs will be preferentially digested under native conditions. After digestion, the 
undigested proteins are heat precipitated and pelleted with centrifugation leaving the HCP-
enriched supernatant for recovery and LC-MS/MS analysis. Benchmarking of this method with a 
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high-purity monoclonal antibody, from the National institute of Standards and Technology 
(NIST), resulted in detection of 60 HCPs which is twice as many as previously reported with 2D-
LC/MS/MS approaches. In contrast to traditional ‘bottom-up’ approaches, this depletion strategy 
can lower the dynamic range up to two orders of magnitude for HCP detection. This approach 
does have a few drawbacks however, including the potential to lose heat-labile HCPs, co-
precipitation of the HCPs with the Ab, and an inherent lack of general applicability for 
characterizing HCP content in non-antibody samples, such as fusion proteins, which may not 
have the same resistance to proteolysis [116,118]. Given the limitations of existing methods, 
novel strategies for sensitive and comprehensive characterization of HCP content in 
biotherapeutic drug substances are needed.  
1.8 Dissertation Outline 
The aim of the work described in this thesis is to develop novel LC-MS/MS workflow 
strategies, including sample preparation, chromatographic separation, and MS/MS activation, for 
characterizing and profiling challenging proteins and labile PTMs. Specifically, Chapter 2 
describes work to adapt LC-MS/MS ‘bottom-up’ workflows for directly detecting native protein 
palmitoylation in proteomic analyses and Chapter 3 discusses our efforts developing a one plate 
LC-MS/MS workflow utilizing chromatographic fractionation of undigested drug substance for 
characterizing host-cell protein content in biotherapeutic drug substances. These findings can be 
applied broadly to inform workflow optimization for studying labile protein modifications and 
detecting low abundant proteins in complex mixtures.  Chapter 4 provides a concluding summary 
of the novel contributions of our work and the broader impact on the field of LC-MS/MS based 
protein analysis. 
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Chapter 2 
 
 
Direct Identification and Site-Specific Analysis of Recombinant N-Ras Palmitoylation  
by Liquid Chromatography-Tandem Mass Spectrometry 
2.1 Introduction 
 S-palmitoylation, referred to as palmitoylation, is a reversible and dynamic post-
translational modification (PTM) that results from the thioesterification of palmitate, a saturated 
sixteen-carbon fatty acid, to a cysteine residue of a protein. This dynamic modification (Figure 
1.6) is essential for intracellular signaling, and is critical in regulating the function of membrane-
associated signaling proteins such as the Ras family of signaling proteins (Figure 2.1) [1,2].  
The Ras family of proteins consists of small GTPases (guanosine triphosphatases) that 
play a role in signaling, cell proliferation, differentiation, and survival [3]. They are well-known 
drivers of many cancers and thus represent attractive targets for the development of anticancer 
therapeutics. All four Ras proteins (Figure 2.1) are farnesylated on a C-terminal CaaX motif, 
which is important for membrane association. However, the farnesyl group alone confers weak 
membrane association, and palmitoylation is needed for stable membrane attachment. In fact, 
drugs inhibiting farnesylation of palmitoylated Ras have failed to promote significant membrane 
dissociation of targeted Ras proteins, and S-palmitoylation was sufficient to retain membrane 
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localization and signaling behavior [4]. However, relatively little is known about cellular 
regulation of palmitoylation, and strategies for inhibiting Ras palmitoylation remain elusive. 
Therefore, studying the dynamics of palmitoylation is vital for developing new therapies 
targeting protein palmitoylation. 
 
 Common biochemical analysis strategies for S-palmitoylation analysis involve 
chemolytic removal of palmitate followed by labeling of the free sulfhydryl with either a 
fluorescent marker for detection, or resin assisted capture of S-acylation sites (acyl-RAC) with a 
sulfhydryl reactive reagent (Figure1.7(a)) [5-7,10]. S-palmitoylation sites have also been 
identified in large scale studies through metabolic labeling in culture with alkynyl analogues of 
palmitic acid (Figure 1.7(b))[8,9,13]. These alkynyl analogues can be coupled to an azide-linked 
fluorescent tag or an affinity reagent via copper-catalyzed ‘click chemistry’ [9-14]  Site specific 
analysis typically has involved the introduction of point mutations, which can be tedious or 
impractical, and this approach is particularly challenging when a protein contains dozens of 
cysteine residues but may only undergo a single modification [10].  
 Modern high-resolution, liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
techniques enable large scale protein sequencing with site-specific resolution for abundant and 
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stable PTMs) [15-17]. In “bottom-up” proteomics, proteins and their PTMs are profiled by 
separating proteolytic peptides over a LC column, analyzing them by online MS/MS, and 
compiling lists of proteins identified through database searches against the entire proteome of the 
host organism (Figure 1.4). However, robust and sensitive methods for the direct detection and 
profiling of palmitoylated proteins by LC-MS remain elusive. Palmitoylation sites are predicted 
for more than 1,000 proteins, yet only a small percentage have been experimentally validated 
[21-23]. 
 LC-MS/MS ‘bottom up’ proteomics protocols calls for the initial enrichment of protein 
classes of interest from cell lysates, digestion of the proteins with trypsin into their constituent 
peptides, sample clean up steps to remove buffer contaminants and concentrate the sample, 
separation on reverse phase (RP) columns with high-performance LC, and subsequent analysis 
with high resolution MS/MS. While these methods are robust and highly generalizable for 
typical proteomics experiments, optimization of each step based on sample-specific 
considerations is necessary. Each of the aforementioned steps presents specific PTM-related 
challenges for analyzing S-palmitoylated proteins that are not easily enriched and can undergo 
palmitoyl loss during sample processing [20], hydrophobic peptides are difficult to maintain in 
solution, are strongly retained on RP columns, and labile PTMs are typically lost during 
conventional MS/MS analysis.. 
S-palmitoylated proteins are typically membrane bound (Figure 1.6) and can be insoluble 
in aqueous buffers potentially making them prone to aggregation and resistant to digestion by 
trypsin without the use of a surfactant. Acyl thioesters are labile functional groups that have a 
propensity to hydrolyze in the presence of bases and/or heat [24,25], and they are known to be 
labile in the presence of the reducing agent dithiothreitol (DTT) [20]. Also, lipidated peptides 
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may be retained on solid-phase extraction (SPE) columns during clean up steps. Furthermore, the 
long fatty acyl chain may contribute to poor ionization efficiency, a prerequisite for sensitive 
detection and efficient fragmentation in MS2. Additionally, acyl thioester linkages have been 
reported to be labile under collision-induced dissociation (CID), leading to neutral loss of the 
fatty acyl group, further complicating identification of acylated peptides [20]. 
Important considerations in limiting palmitoyl loss are the desalting and buffer exchange 
steps during sample cleanup for LC-MS based workflows. After protein digestion and/or 
enrichment, the presence of reagents such as alkylators, reductants, denaturants, and buffer salts 
in digested samples can lead to column contamination, ion suppression, and/or fouling of the MS 
source. Typically, cleanup steps, such as SPE or affinity chromatography, are employed to 
remove these contaminants, however these methods must be compatible with palmitoylated 
peptides. Using SPE filters presents a similar problem to RP chromatography in that it can 
potentially retain hydrophobic peptides. In contrast to RP chromatography, SPE columns are not 
commonly conditioned to prevent strong adsorption of the peptides to the resin and requires 
additional sample transfers between fresh vials, risking further loss of low abundant species to 
vial adsorption. Additionally, any surfactant must be removed before SPE clean up risking 
precipitation of the more insoluble peptides in aqueous buffers. Furthermore, affinity 
enrichments targeting palmitoylated peptides are challenging because palmitate lacks functional 
groups, which typically promote antigenicity for immunocapture methods.  
These challenges may contribute to the poor LC-MS detection sensitivity of low 
abundance peptides, such as palmitoylated peptides, or introduce bias in quantitative 
measurements towards more compatible peptides. In our studies, we opted to eschew these steps 
and instead employ an inline sample cleanup with a pre-column filter, or trap column, within our 
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LC setup. Using an isocratic wash step after LC injection, we can concentrate the digested 
peptides on the trap column and divert the contaminated sample buffer to waste, avoiding the 
analytical column and mass spectrometer entirely.  
 Another area of concern is the removal of surfactant, used to solubilize hydrophobic 
peptides in digestion buffer, prior to LC injection which may result in aggregation or 
precipitation of insoluble peptides. Such removal is a problem as precipitation may result in loss 
of acylated peptides before they can be analyzed, and it could also result in clogging of the LC 
plumbing, especially at higher concentrations. To circumvent this issue, samples were diluted 
into mixed organic-phase buffers containing 35% acetonitrile/ water prior to the surfactant 
degradation in 1% TFA. Furthermore, TFA is known to be difficult to remove from RP columns, 
requiring long wash cycles and contributing to ion suppression. Therefore, it is especially 
important that an inline desalting step is used before introduction of the sample to the analytical 
RP column.  
In this chapter, we identify and address key steps in LC-MS ‘bottom up’ workflows that 
may contribute to loss of palmitoylated species and develop a novel workflow for directly 
detecting and annotating palmitoylated peptides in complex mixtures. Specifically, this novel 
workflow is applied to neuroblastoma Ras viral oncogene homolog (N-Ras), an important 
therapeutic target [3,4] that is palmitoylated proximal to the C-terminal cysteinyl site of 
farnesylation [4,26] (Figure 2.1). No direct detection of a palmitoylated N-Ras peptide has been 
previously reported, presumably due to the inherently challenging characteristics of this non-
antigenic and greasy peptide [22,23].  
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2.2 Experimental 
2.2.1 Preparation of Palmitoylated Peptides. 
Three custom peptides were purchased from ABM (>90% purity) with the following 
sequences: PDFRIAFQELLCLR, MGCVQCKDKEA, ARAWCQVAQKF, based on a previous 
study [20]. Each peptide standard (200 µg) was reacted with 1 μL of palmitoyl chloride (Sigma 
Aldrich) in 10 μL of 100% TFA (Sigma Aldrich) for 10 min at room temperature. The resulting 
mixture was dried under a nitrogen flow. The sample was suspended in 400 μL of 30% 
acetonitrile (singly palmitoylated peptides) or 40% acetonitrile (doubly palmitoylated peptides), 
sonicated for 1 min, centrifuged for 10 min at 13000 RCF. Twice more the supernatant was 
collected and centrifuged for 10 min and transferred to another vial. Palmitoylation was validated 
by mass analysis with an Agilent 6500 series QTOF mass spectrometer. Aliquots were frozen at 
−80 °C for later use. 
2.2.2 Synthesis of Acid Labile Surfactant 
 
Synthesis of (2-methyl-2-undecyl-1,3-dioxolan-4-yl)methanol 
To a dried 50 mL round bottom flask containing 35 mL anhydrous toluene and a stir bar 
was added 2-tridecanone (1.0 eq, 5.0 g, 25.2 mmol), glycerol (2 eq, 3.7 mL, 50.4 mmol), and p-
toluenesulfonic acid (0.02 eq., 96 mg, 0.50 mmol). The flask containing the reaction mixture was 
Figure 2.2 RapiGest SF (Waters) is an acid-labile surfactant that hydrolyzes into 2-
tridecanone and an LC-MS compatible salt.  
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attached to a dean stark apparatus and was heated to reflux at 120 oC for 4.5 h. Every hour, 10 
mL of water/toluene mixture was removed from the collection tube of the dean-stark apparatus 
and then 10 mL of anhydrous toluene was added back to the reaction flask. The reaction mixture 
was washed with (2 x 15 mL) of 5%(aq) sodium bicarbonate and (3 x 15 mL) of distilled water. 
The organic layer was then dried over MgSO4 and concentrated under vacuum affording a clear 
yellow-tinged oil. The oil was purified by flash chromatography on a Telodyne CombiFlash over 
a silica column with a gradient of ethyl acetate and hexanes. Solvent was removed under reduced 
pressure affording a clear white oil. Identity of the product was confirmed by HNMR and CNMR 
in CDCl3. 
Synthesis of 2-((2-methyl-2-undecyl-1,3-dioxolan-4-yl)methoxy)ethane-1-sulfonate 
To an oven dried flask equipped with a stir bar was added sodium hydride (88.1 mg, 2.20 
mmol, 1.2 eq) in anhydrous THF (2.0 mL). Then (2-methyl-2-undecyl-1,3-dioxolan-4-yl) 
methanol (500 mg, 1.84 mmol, 1.0 eq) was added to the solution and stirred under an argon 
atmosphere for 15 min at room temperature. To the stirring solution, 1,3 propane sultone (161 
µL, 1.84 mmol 1.0 eq) was added slowly. The solution was reacted at room temperature for 20 h. 
The reaction progress was monitored by TLC. The reaction was quenched by the slow addition 
of methanol to the stirring mixture. The resulting suspension was then evaporated under reduced 
pressure. The resulting solid residue was then resuspended in ethanol, heated to reflux and 
cooled to room temperature and a white precipitate formed. The suspension was centrifuged at 
3000 rpm in a conical vial for 5 min and then the supernatant was removed, and the wash was 
repeated once more. The pelleted solid was dissolved in dichloromethane and then dried under 
vacuum. The dried residue was then dissolved in distilled water and again centrifuged at 5000 
rpm for 5 min. The aqueous layer was removed, and the solution was lyophilized. Identity of the 
product was confirmed by HNMR and CNMR in D2O. 
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2.2.3 pH Stability Test of Palmitoylated Peptides 
 Into separate Eppendorf tubes containing 400 µL of 50% acetonitrile (aq.) was added 400 
µg of each palmitoylated peptide, referenced and prepared as described, and vortexed until 
dissolved. Then 5 µL of each palmitoylated peptide solution was transferred from these stocks to 
each of 15 vials (3x5 vials) each containing 15 µL acetonitrile and 75 µL of 100 mM PBS where 
the pH was adjusted to pH 5.0, 6.0, 7.0, 8.0, 9.0 respectively. The samples were vortexed and 
then allowed to incubate for 60 min before 5 µL of formic acid was added to each vial. Then 5uL 
of each stock solution was added to a vial containing 15% acetonitrile in 100 mM PBS (5% 
formic acid) as controls. Control groups were prepared for each peptide by adding 5 µL of each 
palmitoylated stock solution to vials containing 15 µL of acetonitrile and 75 µL of 100 mM PBS 
and acidified with 1 µL formic acid. Then 10 µL from each vial was then injected onto a Waters 
5x100 mm CSH C-18 3.5 µm UPLC column and analyzed by an Agilent 6500 series QTOF mass 
spectrometer. Extracted ion chromatograms were analyzed for changes in peak area 
corresponding to the palmitoylated peptides compared to control groups.  
2.2.4 Chromatographic separations and MS/MS analyses 
 All chromatographic separations were conducted with a Thermo UltiMate3000 Nano LC 
pump with house-packed 75 µm x 10 cm 3.5 µm C-8 or C-18 nano capillary columns and an 
IDEX C-8 or C-18 2x20 mm 7 µm trap column. Conditions were flow rate: 0.300 µL/min, 
temperature: 60 ֩C, Solvent A: water (0.1% formic acid), Solvent B: acetonitrile (aq,0.1% formic 
acid). 
Mass analyses were conducted with a Thermo Orbitrap Fusion Lumos mass spectrometer. 
MS1 conditions were ESI voltage: 1780 V, vaporizer temperature: 150 oC, ion transfer tube 
temperature: 300 oC, sheath gas: 10, Aux gas: 1, sweep gas: 0, Orbitrap precursor selection: 150 
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k resolution, scan range: 200-2000, max inject time: 50 ms, AGC target: 4x105, RF lens: 30%, 
dynamic exclusion: 60 s, mass tolerance: 10 ppm. MS2 conditions were: detector: Orbitrap 60k 
resolution, activation: HCD (17, 24, 30), scan rate: rapid, max injection time: 35 ms, isolation 
window: 1.4 Da. Database searches were conducted with Thermo Proteome Discoverer against a 
customized protein database including the synthetic peptide sequences or downloaded from 
UniProt.org. Search parameters were a mass tolerance of 10 ppm for precursors and fragments 
and fully specific peptide termini with ≤ 3 missed cleavages. Variable modifications included 
methionine oxidation and palmitoylation and/or carbamidomethylation depending on the 
experimental conditions.  
2.2.5 Evaluation of Chromatographic Conditions for Palmitoylated Synthetic Peptides 
For evaluation purposes, the three synthetic peptides mentioned above were chemically 
palmitoylated as previously described, combined in 1:1:1 ratio, and diluted to 1 µg/µL in 35% 
acetonitrile/water (0.1% formic acid). The samples were cooled to 5 oC before 1 µg was injected 
onto the column. The gradient for testing column stationary phase was  5-90% B over 60 min 
and the gradient for testing separation temperatures was 25-90% B over 60 min. Extracted ion 
chromatograms were obtained for each peptide with Thermo Xcalibur. 
2.2.6 Evaluation of MS2 Fragmentation Conditions for Synthetic Palmitoylated Peptides  
For evaluation purposes, the three synthetic peptides mentioned above were chemically 
palmitoylated as previously described and diluted to 1 µg/µL in 35% acetonitrile/water (0.1% 
formic acid). Samples were directly injected for MS analysis and [M+3H]3+ precursor ions were 
selected for MS2 fragmentation under CID, HCD, and ETD conditions.  
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2.2.7 Evaluation of Chromatographic Conditions for Palmitoylated Bovine Serum Albumin 
Digest 
 Bovine serum albumin (40 µg, Fisher Scientific) was dissolved into 4 µL of 50 mM Tris 
Buffer (pH 7.6) containing 2 mM TCEP (Sigma Aldrich). The sample was incubated at 60  oC for 
1 h before 8 µL of 50 mM Tris Buffer (pH 7.6) containing 6 M Urea (Fisher Scientific) was 
added. The sample was heated to 90 oC for 10 min, removed from the heat, and 28 µL of 50 mM 
Tris Buffer (pH 7.6) was added. The sample was vortexed, and 2 µg of trypsin (Promega) was 
added before incubation on an orbital shaker at 37  oC for 18 h and desalting on an Oasis HLB 
Elution solid phase extraction plate according to manufacturer’s protocol. The digest mixture 
was then aliquoted into two equal portions and dried on a Speed-Vac evaporator at 40  oC. One 
aliquot was reconstituted in 10 µL trifluoroacetic acid (Sigma Aldrich) and then palmitoylated 
following the previously described protocol. The other aliquot was reconstituted in 10 µL of 50 
mM Tris buffer, pH 7.4 and treated with 20 mM iodoacetamide for 1h at 37  oC. The sample was 
then acidified with 1 µL of 1% formic acid. 10 µg of protein from each sample was combined 
and diluted to a final concentration of 40 ng/µL in 35% acetonitrile/ water (0.1% formic acid). 
100 ng of protein mixture was injected for each replicate. 
2.2.8 Site-Specific Annotation of Palmitoylated Recombinant N-Ras by LC-MS/MS 
Overexpression and enrichment of recombinant N-Ras 
Plasmids expressing N-terminally His-tagged N-Ras with a TEV-linker were generated 
via restriction digest and ligation into p6xHis, pMBP and pGB1 (Protein Core in the Center for 
Structural Biology, Life Sciences Institute, University of Michigan). The human N-Ras gene was 
ligated to the plasmids using SspI and BamHI restriction sites and amplified before 
transformation into BL21 (DE3) E.coli electrocompetent cells. Colonies were selected on (-)His 
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agar plates and BL21 (DE3) E. coli cultures were grown at 37 ˚C to OD600 = 0.8 and the 
temperature was reduced to 18 ˚C for 1 h before induction with 0.4 mM IPTG for 16 hours at 18 
˚C. Cell pellets were resuspended in 50 mM HEPES buffer containing 300 mM NaCl, 10% 
glycerol, 2 mM 2-mercaptoethanol, 0.1% RapiGest, and 0.005% IGEPAL. The cells were lysed 
using a microfluidizer and centrifuged at 16000 rpm for 30 min. Protein concentration was 
measured using DC protein assay (Biorad). The cleared supernatant was incubated with Talon 
cobalt affinity beads (Clontech) for 1 h, washed with 50 mM HEPES, 150 mM NaCl , and then 
incubated for 16 hours with TEV-protease (1:100 w/w, Sigma Aldrich) at 4 oC. The proteins 
were eluted using 50 mM Tris pH 7.0 containing 0.2% Rapigest, and protein concentrations were 
measured using DC protein assay (Biorad).  
Digestion and LC-MS Analysis 
Thawed samples were incubated with 2 mM TCEP at 37 oC for 30 min and diluted 2-fold 
in 50 mM Tris pH 7.0. The protein mixture was digested for 4 h with trypsin (1:20; Promega) at 
37 oC. Samples were concentrated with a Thermo Savant SpeedVac and then reconstituted in 
35% acetonitrile/water containing 1% trifluoracetic acid (v/v) and incubated for another 30 min 
at 37 oC. Precipitated surfactant was pelleted by centrifugation at 13000 rcf for 10 min and the 
supernatants were transferred to an LC-MS vial for analysis. 
Protein samples were injected (10 µL) with a Thermo UltiMate 3000 NanoLC pump and 
separated over a house-packed nanocapillary column (C-8 or C-18, 75 µm x 15 cm; 3 µm 
particles, 100 Å pore density) and a matching stationary phase 2 cm trap column (IDEX) with a 
500 nL/min flow rate at 55 oC. The mobile phase gradient consisting of Buffer A: water (0.1% 
formic acid) and Buffer B: acetonitrile (0.1% formic acid) was initially held at 1% Buffer B for 5 
min with flow diverted from the trap column to waste. At 5 min, flow was diverted to the 
48 
 
analytical column and the gradient was brought to 35% Buffer B (5-10min), then gradually 
raised to 75% Buffer B (10-65 min), and then raised to 95% and held there (65-75 min). MS 
analysis and a database search was performed as stated above with the exception of using HCD 
step-fragmentation (17, 24, 30%) for MS2 analysis. 
2.3 Results and Discussion  
 Previous work by Ji et al. [18] identified three key steps that contributed to  the 
failure of direct palmitoylation detection for three synthetic peptides. These include sample 
processing steps that contribute to S-palmitoyl hydrolysis, LC conditions that lead to strong 
retention and associated poor resolution of the acylated peptides, and MS2 fragmentation 
conditions that lead to neutral loss of the palmitoyl group. We sought to build upon this work by 
addressing each sample processing condition that may lead to loss of this labile group, 
optimizing those conditions to increase the probability of detection by LC-MS, and apply this 
newly developed method for the novel direct detection and site-specific annotation of 
palmitoylated N-Ras.  
For evaluating each sample processing step, we  used the same three peptide standards 
(Peptides 1-3, Figure 2.3) developed by Ji et al.  based on non-tryptic sequences of known 
palmitoylation sites in native proteins. These non-tryptic peptides were chosen because they 
afford good signal during positive ion mode ESI-MS analysis due to having multiple proton 
carrying amino acids. These peptides also model different types of peptide acylation with one or 
two sites available for in situ chemical palmitoylation. Peptide 3 contains a tryptophan residue, 
which is electrophilically labeled by palmitoyl chloride, forming an irreversible and stable acyl 
ketone on the indole ring, thus modeling doubly acylated peptides with a single reversible 
palmitoylation and a second more stable fatty acid, i.e., prenylation or myristylation.  
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2.3.1 Cell Lysis and Protein Extraction 
We began by evaluating each step in an LC-MS/MS workflow for conditions that could 
lead to loss of palmitoylated peptides. Generally, the first step of a typical LC-MS/MS-based 
proteomic workflow (Figure 1.4) is the lysis of cells of interest followed by extraction of the host 
proteome. Since S-palmitoylated proteins are hydrophobic and most likely membrane-bound 
(Figure 1.6), they are largely contained within the insoluble lipid layers of a cell lysate and may 
exhibit poor solubility in aqueous lysis buffers. In targeted studies of membrane proteins, 
hydrophobic proteins are solubilized into extraction buffers with the use of surfactants, such as 
sodium dodecyl sulfate (SDS). These surfactants are important for not only the initial extraction 
but also the continued solubilization of these hydrophobic proteins and peptides throughout the 
workflow. However, there are caveats to using surfactants in LC-MS based analysis, such as 
interference with trypsin digestion, contributing to ion suppression, and adversely impacting 
chromatographic retention, resolution, and peak shape. For example, surfactants can disrupt the 
interactions between a peptide and a column’s stationary phase leading to poor column retention 
and peak broadening, thereby decreasing chromatographic resolution, and increasing the 
likelihood of peptides co-eluting. Peak broadening can also lower the maximum analyte signal 
intensity following ionization, which can reduce the probability of detecting low abundance 
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peptides. Additionally, ionizable surfactants, such as SDS, can be incompatible with MS analysis 
due to ion suppression and adduct formation. These factors necessitate steps to remove surfactant 
from the sample prior to LC-MS analysis resulting in lower throughput and unpredictable protein 
losses, with implications for downstream detection and quantitation. 
LC-MS compatible surfactants offer a viable alternative and have been shown to 
effectively improve protein digestion efficiency in proteomic workflows [19-21] .The analogue, 
2-((2-methyl-2-undecyl-1,3-dioxolan-4-yl)methoxy)ethane-1-sulfonate, or RapiGest SF (Waters) 
has surfactant, denaturant, and electrophoretic properties comparable to SDS. This detergent is 
acid-labile, and upon acidification hydrolyzes into 2-tridecanone, an easily removed precipitate, 
and an LC-MS compatible salt (Figure 2.2). This degradation permits direct MS analysis without 
further sample processing resulting in minimal sample loss or introduced bias for quantitative 
measurements.  
 
RapiGest SF provides a facile solution for extracting and solubilizing S-palmitoylated 
proteins and peptides throughout the workflow. It is a proprietary compound that can be 
purchased through vendors, and it is optimally used at concentrations similar to SDS. However, 
at approximately $50 per milligram, the cost of the detergent limits its practicality in laboratories 
where overhead costs are a concern. To lower the per unit cost, we synthesized our own in-house 
2-((2-methyl-2-undecyl-1,3-dioxolan-4-yl)methoxy)ethane-1-sulfonate). The resulting product 
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can be made in a high-yield, two-step synthesis (Fig. 2.2) at a cost of approximately $50 per 
gram, about three orders of magnitude more cost efficient.  
2.3.2 Evaluation of S-palmitoylation pH Stability 
Under basic pH conditions, thioester bonds are susceptible to nucleophilic hydrolysis 
from hydroxide ions present in aqueous buffers [29]. Most ‘bottom up’ workflows use trypsin to 
digest proteins into their constituent peptides. Trypsin digestions are optimally carried out 
between pH 7.6-8.0 for at least 4 h, and it is highly likely that hydrolysis of palmitoylated 
residues in these digests is substantial. Ji et al previously reported this behavior for the three 
peptide standards, and we sought to validate these results by testing the pH stability of our 
chemically modified peptides over a similar range of buffers (Figure 2.5) and quantify the loss of 
palmitate over the course of 4 hours.  
  
Figure 2.5 Relative retention of S-palmitoylation on three synthetic peptides 
PDFRIAFQELLCLR, MGCVQCKDKEA, ARAWCQVAQKF (Peptides 1-3 
respectively) in 100 mM PBS buffer over 1h. n=3 
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Palmitoylation stability was measured by incubating palmitoylated peptides 1-3 (Figure 
2.5), each in 100 mM PBS buffer at pH 5.0-9.0, for one hour before quenching with formic acid. 
Quantitative analysis was performed by LC-MS on an Agilent QTOF mass spectrometer. Peak 
area ratios integrated from extracted ion chromatograms (EICs) were normalized to the 
respective control groups that were incubated in formic acid buffer. Our results match those by Ji 
et al and indicate that thioesterified palmitate is sensitive to basic buffer conditions, and the 
trends in all three cases indicate that higher pH values tend to increase the rate of palmitate 
hydrolysis. Interestingly, Peptides 1 and 3 were least affected by the higher pH conditions 
retaining at least 85% of their palmitate labels over the course of four hours at room temperature 
and pH 9.0. Interestingly, the behavior of each peptide in these buffers varied. Peptide 1 lost 
approximately 15% of the palmitate label at pH 7.0 while Peptide 3 retained greater than 90% of 
palmitoylation. The data also indicate that Peptide 2, a doubly S-palmitoylated peptide, was more 
sensitive to high pH conditions and only retained 30% of total palmitoylation at pH 9.0. It is 
important to note that the steepest change in palmitate retention occurred between pH 7.0-8.0 
where the total label retention dropped from approximately 78 – 45% respectively.  
We hypothesize that the difference in the observed pH sensitivities may be due to the 
neighboring amino acids present in each peptide. Peptide 2, the most labile peptide, contains two 
lysines which have approximate pKa values of 10. Therefore, at pH 8-9 greater than 90% of the 
lysines will remain protonated in solution. This protonation potentially introduces hydrogen 
bonding interactions between the alkyl oxygen of the thioester and the terminal ammonium of 
the lysine, thus increasing the electrophilicity of the alkyl carbon center and the kinetic rate of 
palmitate hydrolysis. Another possibility is that electrostatic interactions between positively 
charged ammonium of the lysine and free hydroxide may also increase the rate of hydrolysis by 
concentrating the hydroxide anions near the thioester. Peptide 1, however, does not contain 
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lysine which may explain its relative stability compared to Peptide 2. Peptide 3 does contain a 
single lysine, but the steric hinderance of the adjacent acylated tryptophan may serve to protect 
the thioester and slow the rate of hydrolysis.  
While Ji et al. also observed a similar trend in pH sensitivity between the peptides, they 
did not quantify their results, nor did they report such significant loss of peptide 2 palmitoylation 
until after six hours. These data are helpful in evaluating buffer pH conditions most suitable for 
palmitoylation analysis, especially during trypsin digestion. While these higher pH buffers are 
ideal, trypsin digests can still be carried out in neutral buffers with minimal impact on overall 
digestion efficiency. The manufacturer’s protocol for Promega Sequencing Grade Modified 
Trypsin states that trypsin is maximally active between a pH range of 7- 9. Therefore, in order to 
retain palmitoylation throughout our workflow, going forward we carried out all sample 
preparation steps in pH ≤ 7 buffers, including all trypsin digests of palmitoylated proteins in 
neutral pH buffer. 
2.3.3 Chromatographic effects of stationary phase and temperature on  
palmitoylated peptides 
 Having adapted our sample processing workflow to limit palmitoyl-loss from a whole 
cell lysate up to the LC separation step, we next explored LC conditions for compatibility with 
palmitoylated peptides. We initially hypothesized that the underrepresentation of palmitoylated 
peptide identifications in LC-MS/MS based proteome analyses may be primarily due to strong 
peptide retention on C-18 resins. Currently, reverse phase HPLC is the most common LC 
platform for the separation of water-soluble proteins and peptides. Typically, mobile phase 
gradients comprised of formic acid buffered water and a miscible organic eluent, such as 
acetonitrile, are used to elute solutes with increasing strength. This combination of stationary and 
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mobile phases can be adjusted and optimized to fit the specific needs of a study. However, C-18 
columns are readily available and have proven to be reliable and robust for most proteomic 
analyses studying soluble peptides. In cases where membrane proteins are of interest and high 
sequence coverage of hydrophobic regions is desired, gradients need to be strengthened to elute 
the hydrophobic or lipidated peptides. Mobile phase composition can also be strengthened with 
the addition of stronger organic solvents, such as isopropanol, if acetonitrile alone is insufficient. 
However, there are drawbacks to changing mobile phase composition, and the process of 
changing and equilibrating mobile phases, with capillary LC especially, can be time intensive or 
impractical if using a shared instrument with limited availability. Additionally, strengthening the 
organic phase can result in poor chromatographic resolution of more hydrophilic peptides 
resulting in poor sequence coverage during analysis. Often, a more practical solution is to use a 
different column with a less retentive stationary phase, such as C-8 or C-4, or to use high 
separation temperatures to increase solubility.  
It is reasonable to expect that multiply lipidated peptides with a high degree of nonpolar 
amino acid composition, such as membrane associated palmitoylated peptides, may be difficult 
to elute from C-18 columns. We hypothesized that the combination of a C-8 nano-LC column 
with a formic acid buffered water and acetonitrile mobile phase would be capable of eluting 
multiply lipidated peptides and still provide good resolution for both hydrophobic and 
hydrophilic peptides. To test this hypothesis, we compared the LC retention profiles of our three 
standard palmitoylated peptides on both C-8 and C-18 columns (Figure 2.6).  
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Figure 2.6 shows the separation of a sample containing an equiproportional mixture of 
our three palmitoylated peptides at 35 oC with water/acetonitrile on a 10 cm nanocapillary 
column packed with either C-18 or C-8 resin. The graphs illustrate the EICs of the [M+2H]2+ 
ions of the palmiotoylated peptides after separation. Figure 2.6(a) indicates that the peptide 
containing a single palmitoyl group eluted in approximately 80% acetonitrile. However, both of 
the doubly palmitoylated peptides failed to elute on the C-18 resin until the gradient was held at 
95% acetonitrile for 10 min at which point they co-eluted with poor signal-to-noise ratios. A 
subsequent injection of a blank containing 50% aqueous methanol reulted in carry-over of these 
peptides into the next LC run, indicating that some fraction of these peptides were retained on 
the column. This result helped confirm our intial hypothesis that C-18 columns may not be an 
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optimal choice for separation of lipidated peptides, especially peptides with more than one lipid 
group.  
We then evaluated the effects of separating our peptides on a C-8 column under the same 
conditions. Figure 2.6(b) illustrates a significantly improved retention profile with all three 
peptides eluting between 50-65% acetonitrile with good resolution and peak shapes. A 
subsequent injection of a blank containing 50% aqueous methanol showed no carry-over of these 
peptides, indicating that all three peptides were quantitatively eluted from the column. The latter 
behavior is important when quantitative measurements of palmitoylated peptides are desired. 
Overall, we determined that use of C-18 chromatography with an acetonitrile mobile phase 
potentially leads to loss of palmitoylated peptides in LC-MS analyses. Additionally, we 
determined that a C-8 resin is a better choice for separating lipidated peptides under these 
conditions.  
Gradient optimization is an imporant consideration in any LC separation, and due to the 
high concentration of organic phase required to elute our lipidated peptides coupled with the 
close retention times, we increased the organic phase concentration throughout the gradient to 
hopefully achieve better resolution. Therefore, the gradient was adjusted to a 15% acetonitrile 
intial isocratic hold and quickly increased to 35% in the first few minutes followed by more 
gradual increase to 70% over 45 min. We expected these changes to improve the performance of 
the separation and increase resolution between the lipidated peptides. Additionally, temperature 
is a another conditon that affects chromatography. Higher column temperatures can be utilized in  
LC separations to decrease peptide retention times, potentially increase peptide resolution, and 
contribute to sharper peak profiles. Using our adjusted gradient, we explored the effects of 
increasing column temperature from 35 oC to 55 oC for our palmitoylated peptides (Figure 2.7). 
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Comparing results between experiments (Figures 2.6(b) and 2.7(a)), we evaluted the 
effects of our gradient optimization on the retention times of the three lipidated peptides. As 
expected, the optimized gradient provided improved separation with sharper chromatographic 
peaks. Importantly, the increased resolution minimized any co-elution between the peptides. 
Comparing Figures 2.7 (a-b), the temperature increase from 35 oC to 55 oC improved the signal 
of the singly palmitoylated peptide but the other two peaks reamined almost unchanged. 
Interestingly, there was an approximate 2 min shift in the retention time of the singly lipidated 
peptide, in blue, but the doubly lipidated peptides seemed unaffected. The increased signal for 
the singly palmitoylated peptide may be a result of a temperature dependent  unfolding of the 
peptide structure leading to improved ionization. Further work needs to be performed to explain 
this phenonmenon. Overall, we determined that our optimized gradient offers significant 
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improvement to our peak resolution while heated chromatography offers, albeit minor, 
improvements in resolution profiles.  
2.3.4 Evaluating and optimizing MS/MS fragmentation for S-palmitoylated peptides 
 Sequencing a peptide with site-specific resolution of PTMs is achieved through 
fragmenting the peptide with MS/MS. A peptide precursor ion is selected in MS1 and then 
fragmented with some form of dissociative energy introduction resulting in cleavages of the 
chemical bonds making up the peptide, and in ideal circumstances, these cleavages occur 
between the amino acids in the sequence. The subsequent MS2 spectrum is then comprised of 
these ion fragments which can be annotated to sequence the peptide. Ideally, a cleavage is 
introduced between each amino acid in the sequence allowing for complete annotation of the 
peptide. However, the energy levels used in fragmentation need to be tuned to prevent cleaving 
bonds with low activation energy barriers, such as labile PTMs. If the PTM is cleaved without 
retaining a charge, then the MS2 scan will not detect the PTM and is considered a neutral loss 
event. This is potentially a major hurdle in the MS analysis of palmitoylation, and Ji et al. [18] 
reported that palmitoylated peptides were susceptible to neutral loss of the palmitate under 
multiple types of fragmentation methods, including collision induced dissociation (CID), higher-
energy collision induced dissociation (HCD), and electron-capture dissociation (ECD) but 
showed less neutral loss with electron transfer dissociation (ETD). While this phenomenon was 
well-characterized in the study, we sought to evaluate CID, HCD, and ETD on a different 
instrument platform, the Orbitrap Fusion Lumos to select the MS/MS method that provides the 
best combination of good sequence coverage and the least neutral palmitate loss.  
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Figure 2.8 compares the MS/MS spectra of the peptide ARAW(palm)C(palm)QVAQKF from 
CID, HCD and ETD.  CID fragmentation (Fig. 2.8(a)) showed significant neutral palmitate 
(palm) loss, however HCD (Fig. 2.8(b)) resulted in moderate neutral loss. The fragmentation 
profiles observed from both methods provided sufficient sequence coverage for peptide 
identification, however, only HCD provided site-specific annotation of the palmitoylation sites. 
Similar differences between CID and HCD have been observed for other labile PTMs, e.g., 
fucosylation [31].  However, complete coverage of all amino acids in the peptide was not 
observed. Figure 2.8(c) shows the ETD MS/MS spectrum for the same peptide. From ETD, 
complete coverage of the peptide was achieved with site-specific resolution allowing for the 
identification of the palmitoylated amino acids. Similar to the results by Ji et. al., almost no 
neutral loss was observed with only two peaks corresponding to the loss of palmitate from the 
precursor ions. Unlike CID or HCD, which tend to fragment the thioester bond of the palmitate, 
ETD tends to fragment the bond between the β-carbon and the sulfur atom of a palmitoylated 
cysteine producing a slightly different neutral loss signature. Overall, we observed ETD 
outperforming both CID and HCD in retaining the palmitate and in providing complete peptide 
coverage. However, there are some important drawbacks with ETD, which involves introduction 
of a radical anion and transfer of an electron from the radical carrier to a multiply positively 
charged peptide inducing fragmentation of the charge reduced peptide ion. It has been shown 
that peptides best suited for this type of fragmentation are highly charged [30] and/or have 
relatively low m/z ratio (<1,000). While our chemically palmitoylated peptides fall within this 
range, larger scale studies of lipidated peptides using tryptic digests may not. S-palmitoylated 
peptides from trypsin digests tend to have high m/z ratios due to containing one or more large 
acyl chains, and due to originating from membrane associating regions lacking polar amino 
acids.  
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Thus ETD may not be the best overall choice for palmitoylation analysis, and therefore, we 
chose to further explore HCD. 
 Figure 2.9 shows the MS2 spectra from HCD fragmentation of the peptide 
ARAW(palm)C(palm)QVAQKF with 20 and 30% collisional activation energies. While both energy 
levels resulted in cleavages between the modified tryptophan and cysteine residues, 30% 
collision energy resulted in lower peptide coverage and did not allow unambiguous identification 
of the cysteine palmitoylation site.  By contrast, 20% energy did allow site-specific resolution of 
the modified cysteine despite also yielding palmitate neutral loss. These results suggested that 
optimization of collision energy is important and we proceeded to evaluate the other two 
peptides PDFRIAFQELLC(palm)LR (Figure 2.10) and MGC(palm)VQC (palm) KDKEA (Figure 2.11) 
at different levels of collisional energy. Interestingly, the latter two peptides showed improved 
fragmentation behavior at 30% collisional energy than at 20%, unlike 
ARAW(palm)C(palm)QVAQKF. At 40% collisional activation, both MS2 scans resulted in no 
identifiable fragment ions. Overall, we concluded that no single energy level would produce 
optimal fragmentation behavior for every peptide, and therefore, in more complex mixtures, 
HCD step-fragmentation may be ideal. In such approaches, precursor ions are fragmented 
sequentially at multiple energy levels. Although this instrument operation increases duty cycle, 
the probability of acquiring optimum MS/MS data also increases For optimum performance, this 
strategy may need to be coupled with sample enrichment or longer LC gradients to reduce the 
likelihood of co-eluting peptides.  
2.3.5 Evaluating LC-MS workflow with S-Palmitoylated Bovine Serum Albumin 
 Having systematically evaluated and optimized our LC-MS workflow for the direct 
detection of three non-tryptic palmitoylated peptides, we sought to test these conditions on a 
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more complex mixture of chemically palmitoylated tryptic peptides. Bovine serum albumin 
(BSA) contains 35 cysteines, and after digestion with trypsin affords 24 peptides, each with 1-3 
cysteine sulfhydryls available for chemical palmitoylation. This model system increases sample 
complexity and provides an opportunity to evaluate our conditions on a mixture of tryptic 
peptides of varying palmitoylation status. BSA was alkylated with either palmitate or 
iodoacetamide. The presence of carbamidomethylated peptides provides a positive control for the 
analysis and allows us to evaluate the behavior of non-lipidated peptides with our 
chromatography method.  
 
Palmitoylated and carbamidomethylated BSA tryptic peptides were combined and 
separated over a C-8 nano-LC column at 55 oC. Peptides were analyzed by tandem MS with 
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HCD step-fragmentation at 17, 24, and 30% collisional activation energy. The “.raw” files were 
subjected to a database search with Thermo Proteome Discoverer. Retention times of the 
identified peptides were then compared between the palmitoylated and carbamidomethylated 
peptides. Figure 2.12 shows the total identification count for all peptide ions in 90 second bins. 
As expected, the average retention time of palmitoylated peptides was longer than the 
carbamidomethylated peptides, and a majority of the non-lipidated peptides eluted within the 
first 10 min of the gradient. Interestingly, our LC conditions resulted in an effective enrichment 
of lipidated peptides during the separation. Such enrichment is important for complex mixtures 
where lipidated peptides are less abundant than non-lipidated peptides, and co-elution of 
abundant unmodified peptides with lipidated peptides could lead to ion suppression or lack of 
palmitoylated peptide precursor selection for MS/MS. Unfortunately, we only detected 14 out of 
24 of the expected unique palmitoylated peptides. Further investigations failed to identify the 
cause of these missed identifications. It is possible that some peptides were lost during the 
chemical palmitoylation step due to being too insoluble for reconstitution in 35% acetonitrile. 
Other possibilities include the loss of these peptides during the LC separation, or their thioesters 
were not stable and were hydrolyzed prior to analysis. However, complete profiling of artificially 
palmitoylated BSA peptides was only peripheral to the focus of our study, and we did illustrate 
promise of our method for site-specific analysis of a mixture containing tryptic palmitoylated 
peptides. Interestingly, two of the cysteine-containing peptides that were missed 
(MPCTEDYLSLILNR and PCFSALTPDETYVPK) both contain a proline residue immediately 
preceding the palmitoylated cysteine and the truncated non-tryptic peptides TEDYLSLILNR and 
FSALTPDETYVPK were both detected. Further work is needed to determine the root cause of 
the existence of these non-tryptic peptides as new information may be gained about the stability 
of palmitoylated peptides near proline residues. 
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2.3.7 Direct Detection and Site-Specific Analysis of Palmitoylated N-Ras 
 The successful direct, site-specific annotation of 17 palmitoylated peptides, 14 from BSA 
and 3 from synthetic peptides spiked into the sample, encouraged us to apply our method to 
achieve direct detection of natively palmitoylated N-Ras. To obtain this sample, we over-
expressed recombinant N-Ras containing a His-tag, extracted the membrane fraction with 
RapiGest, enriched with a nickel affinity column, then performed trypsin digestion at pH 7.0. 
The surfactant was hydrolyzed in TFA prior to LC-HCD MS/MS analysis with either a C-8 or C-
18 column. The LC-MS ‘.raw’ files were searched with Thermo Proteome Discoverer, and 
search results were filtered for our peptide of interest (Table 2.1). Unfortunately, Proteome 
Discoverer failed to annotate a fully modified N-Ras C-terminal peptide. However, two peptides 
of interest were identified, including a prenylated and methylated C-terminal peptide and a 
palmitoylated and methylated peptide (highlighted in yellow in Table 2.1).  
Interestingly, a peptide was identified containing both the C-terminal methylation and S-
palmitoylation but lacked prenylation. This result was unexpected because farnesylation occurs 
through the acylation of a cysteine sulfhydryl, not through formation of a thioester bond. 
Thioether bonds are significantly more stable then thioester bonds and are therefore not prone to 
hydrolytic cleavage, heat labile, or sensitive to reducing agents. Furthermore, the palmitoylated 
peptide had a retention time of 63 min, near the end of the gradient where, in previous 
experiments, doubly or triply lipidated species tended to elute. This behavior suggested that 
farnesylation may have been lost post column prior to MS1 precursor selection, however, further 
work is needed to validate the existence of this peptide.  
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Additionally, it should be noted that most of the identified peptides contained a missed 
cleavage site, resulting in an N-terminal lysine being present. This missed cleavage is important 
because lysines are basic and sequester positive charges under ESI (+) ionization, thus 
effectively increasing the total charge of the peptide ion. Additional basic residues typically 
results in higher signal intensity and improved HCD fragmentation behavior, which both help 
improve peptide annotations. This consideration is important when building inclusion lists for 
targeted proteomics analyses, and proteases such as Lys-N, which cleaves N-terminal to lysine, 
can potentially be leveraged for more sensitive detection.  
In an effort to determine the root cause of Proteome Discoverer’s failure to identify our 
targeted peptide, we manually searched the MS1 scans for a precursor ion matching the m/z value 
of fully modified N-Ras C-terminal peptide. We were successful in identifying a precursor 
matching the theoretical mass of our targeted peptide, however, the only matching precursor ion 
contained the missed lysine cleavage in its sequence, similar to the peptides identified in Table 
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2.1. In fact, not only was the peptide ion signal abundant, but it had also been selected for 
fragmentation.  The manually annotated resulting MS2 scan is shown in Figure 2.13 for . 
matching the [M+2H]2+ precursor ion of KLNSSDDGTQGC(palm)MGLPC(farnesyl)-OMe, the fully 
modified N-Ras C-terminal peptide.  
 
2.4 Conclusion 
Based on efforts to develop a method for directly detecting palmitoylation events in 
protein digests, we report the first direct identification of N-Ras palmitoylation by LC-HCD 
MS/MS with sufficient sequence coverage for site-specific resolution of each modified amino 
acid. While the targeted peptide ion was present at relatively high signal abundance and was 
selected for MS2 fragmentation producing a high quality spectrum, searches with Proteome 
Discoverer using a variety of search parameters, such as filtering criteria, signal to noise 
thresholds, removal of false discovery rate filtering, adjusting ppm tolerances, and even the use 
of targeted inclusion lists did not yield an identification. The reasons underlying the failure of the 
software remain elusive, but manual searches of the MS1 scans by mass range did require 
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tightening the ppm tolerances to 0.10 ppm from 0.50 ppm to return the target spectrum which 
may hold clues to the underlying cause. Future work should entail the comparison and evaluation 
of different search algorithms for this type of work, as it is possible that other software may not 
have the same challenges.  
Additionally, to further test our initial hypothesis that poor chromatography underlies 
much of the failure to identify S-palmitoylated peptides in proteomics experiments, we injected 
the same N-Ras digest onto a C-18 column. Both Proteome Discoverer and manual search of the 
corresponding data failed to yield the palmitoylated N-Ras peptide. This result suggests that C-
18 chromatography with an acetonitrile/water mobile phase gradient is not suitable for LC-MS 
analysis of S-palmitoylated peptides. Overall, we successfully achieved the novel direct 
detection and site-specific analysis of N-Ras palmitoylation by LC-MS and have built a 
foundation for future LC-MS strategies targeting analysis of global S-palmitoylation and other 
lipid PTMs. 
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Chapter 3 
 
 
Improving Detection Sensitivity for Host-Cell Protein Characterization with Liquid 
Chromatography-Tandem Mass Spectrometry 
3.1 Introduction 
 Host cell proteins (HCPs) are native proteins derived from a host organism used to 
express biotherapeutic proteins for drug substances (DS), such as therapeutic antibodies and 
fusion proteins [1,2]. HCPs may be unintentionally co-purified with a DS as process-related 
impurities, and the presence of these impurities in a DS may present problems in drug 
performance through eliciting immune responses in patients or contributing to the instability of 
drug formulations [2-5]. Therefore, measuring HCP levels to ensure depletion throughout 
manufacturing process development and at release testing is critical [6,7]. Purification steps 
during the manufacturing of a DS nearly completely deplete HCPs, and they are, therefore, at 
very low levels, often 100 parts per million (ppm) or less relative to the therapeutic protein [6]. 
However, these low levels present an analytical challenge for HCP identification and 
quantitation, as the high levels of therapeutic proteins can interfere with HCP detection. 
 Liquid chromatography- tandem mass spectrometry (LC-MS/MS) “bottom-up” 
proteomics offers a highly sensitive, semi-quantitative method for HCP characterization to 
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support downstream purification process development [8,9]. Using an LC-MS/MS ‘bottom-up’ 
approach, HCPs can be identified by separating proteolytic peptides with one dimensional (1D) 
or two dimensional (2D) LC [10], analyzing them withMS/MS [11], and conducting database 
searches against the entire proteome of the host organism.  
One approach to enrich for residual HCPs prior to LC MS/MS analysis, is to precipitate 
biotherapeutic antibodies (Abs) from a sample after overnight native trypsin digestion (Figure 
3.1) [12]. Developed at Eli Lilly, the principle hypothesis of this method is that the Ab in its 
rigid, folded structure will have a slower kinetic rate of digestion by trypsin than natively folded 
HCPs, and as a result, HCPs will be preferentially digested under native conditions. After 
digestion, the undigested proteins are heat precipitated and pelleted with centrifugation leaving 
the HCP-enriched supernatant for recovery and LC-MS/MS analysis.  
 
In contrast to traditional ‘bottom-up’ approaches, this depletion strategy can increase 
dynamic range up to two orders of magnitude for HCP detection. This approach does have a few 
drawbacks however, including the potential to lose heat-labile HCPs, co-precipitation of the 
HCPs with the Ab, and an inherent lack of general applicability for characterizing HCP content 
in non-antibody samples, such as fusion proteins, which may not have the same resistance to 
proteolysis [13,14]. 
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Recently, a novel hydrophilic interaction chromatography (HILIC) fractionation 
approach has shown potential for characterization of impurities in Ab products [14,15]. In HILIC 
separations, the strength of a protein’s interaction with the polar stationary phase of the HILIC 
column is largely dependent on protein size and the number of charged residues [16]. In practice, 
the elution order has been observed to be mostly determined by molecular weight, with low 
molecular weight Ab related species eluting first [14,15].  
 Wang et al. recently implemented off-line HILIC fractionation to separate HCPs from the 
therapeutic protein [15]. This fractionation approach further improves the dynamic range with 
enhanced depletion of therapeutic proteins from the sample. In this method fractions were 
collected over the course of a HILIC separation with fractions containing therapeutic protein 
pooled and analyzed separately from HCP fractions. The low protein concentration of the HCP 
fractions enables higher volume sample loading during subsequent LC-MS/MS analysis and 
effectively increases the detection sensitivity for low level impurities. Additionally, the 
denaturing effects of high-acetonitrile concentrations [17] in HILIC separations ensures 
dissociation of strongly interacting HCPs that may co-precipitate. However, this approach has 
some practical drawbacks. The first concern is related to the multiple transfers of fractions 
between vials. Sample manipulation, such as these transfers, carry the risk of HCP loss due to 
adsorption to the vials they are transferred between and stability loss after the pH changes and 
concentration steps [6]. Second, the throughput is lower than the Huang et al. [13] native 
digestion method, and the manual workload is higher. Third, the method needs to be optimized 
for each therapeutic protein because the initial high organic phase in HILIC gradients can cause 
many therapeutic proteins to precipitate causing potential loss of HCPs and clogging of LC 
columns. Also, the LC gradients and fraction collection windows need to be optimized for proper 
separation of each sample. Ideally, a general protocol could be developed which limits sample 
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specific considerations and optimizations.  Here, we developed an automated HILIC 
enrichment LC-MS/MS workflow that builds upon the previous offline HILIC fractionation 
method. To improve the throughput and practicality of this method, we aimed to streamline the 
workflow and develop a generalized platform for LC-MS/MS based HCP characterization and 
quantitation that limits protein specific optimization requirements, increases throughput, and 
decreases overall handling of the samples between steps.  
3.2 Experimental 
3.2.1 Materials 
Recombinant IgG1 Abs (BMS mAb 1 purified drug substance and BMS mAb 2 purified by 
protein A column), fusion proteins (BMS Fp 1, BMS Fp 2, BMS Fp 3), and Chinese hamster 
ovary (CHO) null strain material (containing HCPs without drug substance) produced by Bristol-
Myers Squibb (Hopewell, NJ) were used in this work. Humanized IgG1κ monoclonal antibody 
standard RM 8671 was purchased from the National Institute of Standards and Technology 
(NIST, Gaithersburg, MD, NIST Ab). All chemicals were reagent grade or better. Ammonium 
formate, ammonium hydroxide solution (~1 M in water), DL-dithiothreitol (DTT), dimethyl 
sulfoxide (DMSO), and Trizma pre-set crystals (pH 7.6) were purchased from Sigma-Aldrich 
Co. (St. Louis, MO). Water and acetonitrile (LC-MS grade), formic acid (FA), and 
trifluoroacetic acid (TFA) were obtained from Thermo Fisher Scientific (Rockford, IL). Urea 
(crystalline) was purchased from Alfa Aesar (Tewksbury, MA). Sequencing grade modified 
trypsin was obtained from Promega (Madison, WI). Pre-mixed chromatographic solvents (water 
containing 0.1% TFA, and acetonitrile containing 0.1% TFA), were from J. T. Baker Chemical 
Co. (Phillipsburg, NJ). 
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3.2.2 Offline HILIC Sample Preparation  
For assessment of biotherapeutic protein solubility in mixed solvent solutions, BMS mAb 
1 (88 mg/mL) was diluted to 4 mg/mL into sample buffer containing aqueous acetonitrile with 
0.1% trifluoroacetic acid (TFA) to achieve final compositions of 10, 15, 20, and 25% (vol./vol.) 
water. Protein solubility was assessed visually at room temperature and at 4 oC over 24 h. NIST 
Ab, BMS mAb 2 and BMS Fp 1-3 were diluted from their respective stocks to 5 mg/mL into 
25% water/75% acetonitrile (0.1% TFA) and the solubility of each sample was assessed 
observationally at room temperature over 24 h.  
 For assessment of gradient and chromatographic resolution of HCP proteins from 
biotherapeutic protein, 20 µg of BMS mAb 1 (88 mg/mL) was diluted into 200 µL of 25% water/ 
75% acetonitrile (0.1% TFA) with or without 20 µg of spiked HCP from CHO standard null 
strain material. A 200 µL injection volume was utilized for each sample. 
3.2.3 HILIC Separation Parameters and Fraction Collection  
A Waters ACQUITY UPLC I-Class system was used for all HILIC separations with an 
ACQUITY UPLC BEH glycoprotein amide column (300 Å, 1.7 µm, 2.1 x 150 mm, Waters, 
Milford, MA). The column was set at 60 °C and the mobile phase solvents were HPLC grade 
water (0.1% TFA) as Buffer A and acetonitrile (0.1% TFA) as Buffer B. The samples were 
separated over 24 minutes at a flow rate of 0.200 mL/min. Gradient: Initial 28% A (0-2 min) and 
then ramped 28-42% A (2-24 min). To rinse the column of any residual contaminants the 
gradient was ramped 42-99% A (2 min) held at 99% A (3 min), and then re-equilibrated at 28% 
A (11 min). UV chromatograms were acquired using a PDA detector at 280 nm and 215 nm 
wavelengths using Waters Empower Software. Fractions were collected by an Acquity Fraction 
Manager in 5 mL wells of a 48- deep well plate. Fraction 1 was collected from 2.00-11.50 
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minutes, Fraction 2 was collected from 11.50-18.50 minutes, and Fraction 3 was collected from 
18.50-24.00 minutes. For HCP characterization, all samples were prepared as a final 
concentration of 5 mg/mL in  25% water and 75% acetonitrile and 0.1% TFA. NIST Ab (10 
mg/mL stock) was prepared at 2.5 mg/mL. For each sample, 200 μL injections were performed 
until 1.0 mg of protein was loaded onto the column, and the fractions were collected from one 
HILIC run.  
3.2.4 Trypsin Digestion  
Ammonium hydroxide solution (10% in acetonitrile) was added to each fraction to adjust 
pH to 6-8 (~50 μL per mL) before each fraction was concentrated to less than 50 μL under 
nitrogen flow using a Glas-Col gas inlet, heated Basic Heated ZipVap Evaporator for 96-well 
plates set to 40°C. Concentrated or dried samples were reconstituted with 200 μL of digestion 
buffer containing 2.0 M urea and 50 mM tris-HCl (pH 7.6). Fractions were mixed to dissolve all 
protein, then combined with 2 µL of 50 mg/mL DTT solution and mixed again. Fractions were 
then incubated for 30 min at 60 °C. After cooling to room temperature, each fraction was treated 
with 2.5 µg of trypsin, mixed, and incubated at 37 °C for 18 h. 
3.2.5 LC-MS/MS Analysis of Digested HILIC Fractions  
The total volume of the digest for each HILIC fraction (~200 µL) was injected for UPLC-
MS/MS analysis unless otherwise specified. Tryptic digests were separated using a Waters 
ACQUITY UPLC CSH C18 column (1.7 μm, 2.1 x 100 mm) on a Waters ACQUITY UPLC 
system (Milford, MA). The mobile-phase Buffer A was water (0.1% FA) and Buffer B was 
acetonitrile (0.1% FA). Separation was performed at a column temperature of 60 °C with a 
mobile-phase gradient as reported by Lagassé et al [115]. On-line mass spectrometric analysis 
was conducted using an Orbitrap Fusion Lumos Mass Spectrometer (Thermo Scientific, 
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Waltham, MA) in positive ion mode utilizing an orbitrap for MS1 scans and an ion trap for 
precursor selection and MS2 scans.  MS1 settings were as follows: Electrospray voltage : +3500 
V, sheath gas: 30, Aux gas: 7, sweep gas: 1, ion transfer tube: 300 oC, Vaporizer: 150 oC, 
Orbitrap precursor selection: 120k resolution, scan range 230-1500 m/z, max inject time: 50 ms, 
AGC target: 4x105, RF lens: 30%, dynamic exclusion: 60 s, mass tolerance: 10 ppm, MS2 
settings were: activation: HCD, scan rate: rapid, max injection time: 35 ms, Isolation window: 
1.4 Da 
3.2.6 Peptide Identification and Protein Quantitation  
MS/MS data were searched for HCP identification using Byonic 3.1.0 (Protein Metrics, 
San Carlos, CA) against a customized protein database including the therapeutic protein 
sequence and the CHO or mouse proteome, as appropriate, downloaded from UniProt.org. 
Search parameters were set as follows: mass tolerance as 10 ppm for precursors and 0.4 Da for 
fragments, fully specific peptide termini with ≤ 3 missed cleavages, and protein FDR cutoff at 
1%. N-terminal glutamine conversion to pyroglutamate was considered a common variable 
modification. Protein hits with |Log Prob| score lower than 3.0, decoys, and common protein 
contaminants were excluded. For quantitation, only proteins with at least 3 unique peptides of 
sequence length 6 or greater were included. All digested samples were spiked with 5000 fmol of 
Waters MassPrep enolase digestion standard (dissolved in 1 mL water) to be used as internal 
calibrant. Absolute quantitation was completed with Progenesis QI. 
3.2.7 Digestion of Proteins in Reducing and Denaturing Conditions Following the “Native 
Digestion” Protocol 
 All samples were diluted to 5.0 g/L in 50 mM tris-HCl (pH 7.6) to a final volume of 200 
μL. For samples in reducing conditions, 2 μL of 50 mg/mL DTT solution was added to the 
buffer. For samples in denaturing conditions, 2.0 M urea was added to the 50 mM tris-HCl (pH 
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7.6) buffer. Each sample was digested, reduced, and precipitated according to the protocol 
described in Huang et al [13]. 
3.3 Results and Discussion 
 The aim of this work was to develop an LC-MS/MS based, semi-automated platform for 
HCP analysis in biotherapeutic drug substances. We built upon a previously described HILIC 
fractionation method [15] to develop robust sample preparation and HILIC separation conditions 
which can be broadly applied to characterize HCP content in most biotherapeutics with 
minimum sample specific optimizations. Additionally, we evaluate both the qualitative and 
quantitative sensitivity of our advanced HILIC method compared to native digestion combined 
with LC-MS/MS analysis. A flow chart of our developed HILIC fractionation method and LC-
MS/MS analysis is shown in Figure 3.2. Our focus was primarily on optimizing the HILIC 
fractionation procedure to increase analytical throughput, with a plate-based approach, and 
optimizing separation parameters for greater generalizability across different DS and protein 
classes. 
 
 
UPLC w/ 
Fraction 
collector 
HILIC 
Column 
6x8-5mL 
Plate 
Heated Plate 
Concentrator 
Trypsin 
Digestion 
UPLC  Reverse 
Phase Column 
Thermo Fusion 
Lumos w/ Ion Trap 
Figure 3.2. Advanced HILIC fractionation method workflow for HCP 
characterization in biotherapeutic proteins. 
82 
 
3.3.1. Developing a Universal, Automated HILIC Fractionation Method for HCP 
Characterization 
 The first step in our workflow is offline- HILIC fractionation of diluted DS. In contrast to 
reverse phase (RP) chromatography, HILIC separation uses a polar stationary phase, and 
therefore, the gradients are initiated with a high concentration of organic mobile phase and 
increase in polar mobile phase to elute retained polar analytes. Drug substances can be carefully 
formulated to achieve protein concentrations up to 100 g/L or more [18]. This high concentration 
is problematic for separations on typical analytical columns, which have limited loading 
capacity, and thus dilution prior to injection is necessary. Additionally, HILIC columns require 
long equilibration periods to re-establish the desired mobile phase concentration and water layers 
on the polar resin bed. Disruption of this layer can lead to retention time shifts between 
injections and poor reproducibility [19]. Injections of samples composed of high aqueous 
concentrations can disrupt the equilibrated column leading to partial breakthrough of unretained 
proteins [20,21]. This problem can be avoided simply by preparing protein samples in a buffer 
closely matching the initial mobile phase composition. This solvent composition matching is 
especially important with high injection volumes that exceed the total column volume. However, 
biotherapeutic proteins, such as antibodies which exhibit high water solubility due to their 
relatively low isoelectric point (pI) values [18], lack the solubility necessary to dissolve in high 
acetonitrile concentrations. Wang et al. addressed this issue by carefully formulating buffers 
composed of solubilizing reagents, such as trifluoroacetic acid  and DMSO, or by using multiple 
small injections of highly concentrated aqueous DS to avoid disrupting the equilibrated column. 
However, these conditions are sample specific, thereby increasing the method development time 
and limiting the overall feasibility of this method as a universal platform across different protein 
classes. We sought to improve upon this strategy by evaluating the solubility of multiple DS in 
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various buffer compositions in order to identify a single sample buffer composition that is 
compatible with the HILIC mobile phase buffers and maintains solubility across different types 
of biotherapeutic proteins. 
 
 Additionally, the sample must remain soluble on the column throughout the gradient to 
prevent potential column clogging from precipitated material and to avoid loss of the sample to 
maintain accuracy of absolute peptide quantitation in the later steps. Each protein sample has a 
‘limit of solubility’ in high organic concentration mobile phase which needs to be considered 
when developing the HILIC gradient (Figure 3.3). Therefore, an optimized gradient needs to be 
designed with a high enough aqueous phase throughout the separation to maintain solubility of 
the samples and provide sufficient resolution for fractionation across multiple biotherapeutic 
proteins.  
 To address these concerns, we first aimed to determine the minimum concentration of 
water needed to completely solubilize most biotherapeutic proteins in our mobile phase buffer 
(H2O/acetonitrile, 0.1% TFA) and then match the initial gradient conditions on the HILIC 
column with the same buffer composition. It is important to note that, when preparing the 
samples, order of addition is important to ensure the protein remains soluble and to prevent 
Figure 3.3. Sample solubility is dependent on buffer composition which needs to 
be balanced with an initial high organic mobile phase for HILIC separation of 
biotherapeutic proteins from residual HCPs. 
Ab 
HCPs 
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precipitation of the proteins during the dissolution of organic solvents or highly concentrated 
acids. Pre-mixing the buffer components prior to the addition of the DS to the sample showed to 
be the best practice to avoid precipitation of the protein samples during addition of organic 
solvent or concentrated acid.  
We evaluated the solubility of the Bristol-Myers Squibb (BMS) proprietary therapeutic 
monoclonal antibody (mAb) BMS mAb 1 (88 g/L stock, 5 g/L final) over a range of organic 
phase buffer concentrations (Figure 3.4, Table 3.1). We monitored the solubility of the mAb over 
24 h by visual inspection of the mixed sample at 5 and 25 oC. The presence of white, cloudy 
precipitate indicates a high degree of precipitation, and a completely homogenous and clear 
solution was considered indicative of good solubility (Figure 3.4). Our observations indicated 
that BMS mAb 1 was insoluble in less than 20% aqueous buffers and remained partially soluble 
until a composition of 25% aqueous phase or greater was reached. Additionally, it was observed 
that this solubility was temperature dependent, and when these samples were placed in a 
refrigerated autosampler (5 oC), the samples would become insoluble and precipitate (Table 3.1) 
at these organic phase concentrations. This temperature sensitivity explains the necessity for 
buffer additives in the method published by Wang et al. [15] which reported solubilizing some 
samples in up to 28% aqueous buffer. Therefore, by preventing refrigeration of the mixtures, we 
can potentially improve sample solubility and eliminate the need for disrupting equilibrated 
column conditions with compounds such as DMSO. 
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BMS mAb 1 was determined to be soluble at room temperature over 24 h in 25% aqueous buffer 
which fits well within the limitations imposed in a HILIC gradient separation. Although these 
solvent conditions are compatible with this particular DS, to evaluate  their wider applicability 
we compared the same conditions for six different proteins representing two distinct 
biotherapeutic protein classes, mAbs and fusion proteins (Fp). All proteins were added to room 
temperature buffers containing 25% water in 0.1% TFA and assessed for solubility (Table 3.2). 
Five proteins were observed to be soluble in these conditions with only one protein (BMS Fp 3) 
lacking sufficient solubility. This higher insolubility is possibly attributable to a high degree of 
sialylation of the O-glycans of this particular protein, further lowering its pI, and decreasing the 
Aqueous composition: 10% 15% 20% 25% 
Figure 3.4. BMS-mAb 1 solubility in mixed phase buffers (5 g/L) in H2O/MeCN (0.1% 
TFA). 
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solubility in acidified acetonitrile or non-polar mobile phases. Additional considerations would 
be required for analyzing this specific sample, such as deglycosylation with PNGase F or 
marginally increasing the water content of the buffer.  Overall, these buffer conditions appeared 
mostly universal across two different protein classes reducing the need for sample specific 
optimization except in specific circumstances like our highly glycosylated protein.  
 
 The next areas we addressed were the selection of a universally applicable HILIC 
gradient and automation of the fraction collection. In the Wang et al. method, fractions were 
manually collected with microcentrifuge tubes and then pooled into three distinct fractions: a 
pre-mAb fraction, the mAb fraction, and a post-mAb fraction (Figure 3.5). The gradient was 
previously optimized for different therapeutic proteins based on their buffer compositions. For 
example, BMS mAb 1 was injected in pure water at 100 mg/mL whereas NIST Ab was injected 
in 28% water with 5% DMSO. Both of these samples required different HILIC gradients to 
prevent chromatographic breakthrough with the some of the mAb eluting with the solvent front 
and to retain resolving capacity of the column. In order to reduce workload requirements and 
improve the throughput of the method, we added a Waters Acquity fraction manager, which 
enables automated fraction collection based on time dependent collection parameters. Due to the 
high degree of resolution achieved with the HILIC gradient used in Figure 3.5, we devised a set 
of fraction collection parameters that work across a wide variety of similarly sized proteins using 
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the same generalized gradient. 
 
 An advantage of offline fractionation is that larger volumes of DS can be fractionated, 
and thus higher volumes of low abundant HCPs will be available for digestion and analysis. 
Additionally, if a high degree of separation is achieved and DS is effectively depleted from HCP 
fractions, higher volume injection of the corresponding proteolytic peptides is feasible in the LC-
MS/MS analysis, increasing the abundance of HCPs. For comparison, the  native digestion 
protocol by Huang et al. [13] digests 1.0 mg of Ab and injects 1/4 of the total volume for LC-
MS/MS analysis because samples with higher concentrations would require further depletion of 
the mAb from the sample in order to prevent overloading of the analytical RP-LC column and 
increasing background peptides from the digested Ab. We expected that injecting a greater 
amount of HCP enriched fractions for LC-MS/MS analysis should further increase our sensitivity 
for HCPs in the sample, however, it would also require high loading conditions, more than 250 
µg protein, during the HILIC step which could potentially affect the chromatography and the 
quantitative capability of the method.  
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Figure 3.5. HILIC separation of biotherapeutic proteins and HCPs offers sufficient 
resolution to clearly separate fractions into three collection windows. Graphic 
credit: Wang et al. 
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 To evaluate our analytical HILIC column’s capacity to both resolve and quantitatively 
elute our samples, increasing volumes of BMS mAb 1 (5 mg/mL) were injected and separated 
with an initial mobile phase of 28% water. Figure 3.6 shows example UV-chromatograms from 
300, 400, and 500 µg injections, acquired at 280 nm. The peak areas were integrated (Table 3.3) 
to validate that no loss of protein to precipitation or column retention occurred. These results 
indicate that quantitative linearity was maintained up to 1000 µg of BMS mAb, however larger 
injection volumes might require a larger diameter column to prevent band broadening.  
Having developed working HILIC separation conditions, we next sought to automate the 
fraction collection parameters which may be sample specific. How strongly a column retains 
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Figure 3.6. UV chromatograms (280 nm) of BMS-Ab 1 on a 2.1x100 mm BEH glycoprotein 
amide column. 
400 µg 
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material with a given gradient is dependent on the number and strength of hydrophilic 
interactions between the protein and the stationary phase [14,20]. HILIC column loading 
conditions involve high organic phase solvent which may denature proteins. Acetonitrile disrupts 
the hydrogen bonding interactions between amino acids and limits higher order structure 
formation; therefore, column retention is typically a function of the number of polar groups 
available for interaction with the stationary phase, such as polar side chains and the amides in the 
protein backbone. The number of interacting groups is therefore protein size dependent, and 
smaller proteins tend to elute first. However, there are other variables, such as the abundance of 
highly polar amino acids or PTMs which increase the overall polarity and retention profile of a 
protein, which should be taken into consideration when predicting retention characteristics 
[20,21]. 
Timing the fraction collection windows such that one set of parameters will apply across 
different samples necessitates that the main therapeutic protein peaks, like those shown in Figure 
3.6, exhibit similar retention times between samples. We designed our collection parameters for 
a 1.0 mg injection of BMS mAb 1 to collect three fractions, where the first and third fractions 
contain HCPs, while the second fraction contains the therapeutic protein. We set our fraction 
collection windows based on the retention profile of BMS mAb 1, where the main therapeutic 
peak eluted from 11.5-17 min. We then compared the retention time profiles between three 
mAbs (Figure 3.7). UV-chromatograms of each sample shows similar profiles and retention 
characteristics between mAbs, which was expected as they are all similarly sized proteins. 
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 Fraction windows for these samples indicated by the red dotted- lines in Figure 3.7 
showed effective fractionation for all three proteins. NIST mAb, a well-characterized and 
purchasable monoclonal IgG standard purified from a Chinese hamster ovary (CHO) culture, 
exhibited significant retention profile overlap with BMS mAb 1 and eluted from 12-17.5 min. 
However, BMS mAb 2, another BMS proprietary therapeutic antibody, exhibited a broader peak 
profile and eluted from 11.5 to 19 min indicating the need to widen the fraction 2 collection 
window another 30 sec. According to two previous studies [14,15], HCPs almost entirely elute in 
fraction 1 (Figure 3.6), and subsequent studies by Wang et al., characterizing HCP content in 
NIST mAb and BMS mAb 1 using HILIC fractionation, reported less than 2% of total HCP 
content detected in fraction 3. Therefore, it is crucial to accurately define the collection endpoint 
for fraction 1 to separate the therapeutic protein from HCP content. However, since fraction 3 
offers little informative value, optimizing the collection endpoint for fraction 2 after the main 
peak is of lesser importance. 
Figure 3.7. UV chromatograms (280 nm) of sample Abs on 2.1x100 mm BEH glycoprotein 
amide column show similar retention profiles between antibodies. Fraction windows can 
thus be generalized between Abs. 
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We concluded, from these results, that these parameters required no further optimization 
for IgG-based mAbs. We next examined how general these parameters are across different types 
of proteins by characterizing two BMS proprietary fusion proteins, BMS Fp 1-2 (Figure 3.8). 
Interestingly, both fusion proteins eluted later than NIST mAb. BMS-Fp 1 eluted from 17-25 
min, and BMS Fp 2 eluted from 14.5-19.5 min, indicating that some optimization between 
different protein types is necessary. However, separation of the fusion proteins from the early 
eluting HCPs was observed. Notably, both fusion proteins showed significant peaks in the 
fraction 1 collection window.  These peaks were later determined to be low-molecular weight 
(LMW) fragments of the fusion proteins. This observation is a concern when considering this 
fractionation method, as LMW are common in biotherapeutic DS. Therefore, sample-specific 
optimizations may be necessary when contaminating LMWs are present. However, widely 
available automated fraction collection systems that can monitor peak formation and separate 
fractions accordingly may be better suited as part of a HCP characterization platform. 
Furthermore, both fusion proteins are smaller than the mAbs we tested, and the longer 
retention times were therefore unexpected. This behavior is possibly due to the slightly higher 
degree of glycosylation of the two fusion proteins. Additionally, the lower abundance of 
disulfide bonds in the fusion proteins compared to the mAbs enables more complete denaturation 
of the proteins in organic buffers and increases the protein-column interactions. Overall, our 
chosen parameters worked across each of the Abs we characterized and provided a basis for our 
HILIC platform. 
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Proteins can adsorb to the surfaces of plastic and glass containers [22-27] used in sample 
processing which contributes to quantitation errors and poor detection sensitivity of low 
abundance species. This problem is compounded with multiple transfers between containers and, 
similarly, this phenomenon is likely to occur when passing a protein or peptide solution through 
a filter or membrane. Therefore, limiting the number of sample transfer steps, including removal 
of filtration and buffer exchange steps, is important in limiting the potential loss of HCPs. In our 
efforts to improve upon the HILIC fractionation method reported by Wang et al. [15], we sought 
to eliminate as many sample transfers as possible by using a plate-based workflow that collects 
each fraction into a single well (Figure 3.2). We implemented a 48- deep well (5 mL) plate that 
can pool each fraction into a single well, resulting in three distinct fractions at the end of our 
gradient and eliminating the pooling step. Furthermore, the following steps from sample 
concentration through trypsin digestion could be completed without transferring the samples 
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Figure 3.8. UV chromatograms (280 nm) of NIST Ab and BMS Fp 1-2 on a 2.1x100 mm BEH 
glycoprotein amide column show similar retention profiles between the fusion proteins but not  
for the Ab. Fraction windows need to be optimized between proteins classes. 
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between vials or plates, reducing any sample handling that can result in protein loss. This 
strategy also increases the throughput of the method where up to sixteen samples per plate can be 
fractionated in tandem, concentrated and digested simultaneously, and then sequentially analyzed 
with LC-MS/MS.  
3.3.2. Identifying HCPs in Abs by HILIC Fractionation LC-MS-MS 
Ultimately, our aim with the developed HILIC fractionation method is to achieve 
industry leading sensitivity for detecting and identifying low abundance HCPs in purified 
downstream biotherapeutic protein samples. However, most DS have been subjected to multiple 
purification steps (Figure 1.8) [6,28,29] and only contain a few detectable HCPs, if any at all. 
This low HCP concentration presents a problem for evaluating the sensitivity of our method with 
a purified DS which may contain only one or two detectable HCPs, not ideal when building a 
statistically relevant comparison of the methods. Therefore, for method evaluation purposes, we 
analyzed the HCP content in an upstream product, BMS mAb 2 that contained approximately 
3000-5000 ppm HCP after Protein A purification [28,29]. Similarly, NIST mAb is a well-
characterized mAb standard with approximately 2000 ppm HCP [30], and it can be used as a 
benchmark for evaluating our method’s performance [30]. 
Our strategy to achieve even greater sensitivity in analysis, was to perform our 
experiments on a Thermo Oribtrap Fusion Lumos mass spectrometer, a sensitive instrument with 
a near-state-of-the art 40 Hz acquisition rate and capable of both ion trap collision induced 
dissociation (CID) and higher energy CID (HCD). Resulting ‘.raw’ files were searched against a 
compiled ‘.fasta’ database using the Byonic (Protein Metrics, Cupertino, CA) search algorithm 
outputting a list of protein identifications. Comparing our HILIC fractionation method result list 
to the native digestion method [13] provides a benchmark from which we can evaluate the 
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sensitivity of our method. The native digestion method offers the highest sensitivity LC-MS/MS 
analysis to date, with exception of the Wang et al. method [15] that serves as the foundation of 
our workflow.  
We began assessing our automated HILIC fractionation method by analyzing the HCP 
content of BMS mAb 2, the upstream purification product, and NIST mAb with our defined 
workflow (Figure 3.2), filtering the resulting lists to remove false positive identifications. The 
resulting lists were then compared to a parallel experiment that followed the native digestion 
protocol. Both experiments were repeated in triplicate for BMS mAb2 and NIST mAb, and the 
total number of positive hits identified by each method was averaged and compared (Table 3.4, 
yellow columns).  
 Our fractionation method on average identified 477 HCPs in BMS mAb 2 and 45 HCPs 
in a NIST mAb sample over the three runs. Conversely, the native digestion method averaged 
only 281 HCP identification in BMS mAb 2 and 41 HCPs in the NIST mAb sample. Our results 
indicate that our HILIC fractionation method resulted in more total positive identifications than 
the native digestion method for both proteins, and BMS mAb 2 showed an almost 2-fold increase 
in total positive identifications. 
 
After filtering out the proteins that were identified by both methods, the resulting lists 
were comprised of protein identifications that were unique to their respective methods. Again, 
the total unique positive identifications were totaled and averaged (Table 3.4, green columns). In 
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both samples, the HILIC method outperformed the native digestion method and totaled more 
unique identifications with more than 50% of the NIST mAb total identifications being unique to 
their respective methods. Similarly, for BMS mAb 2, the HILIC method resulted in 276 unique 
identifications that were not detected with the native digestion method. However, it is important 
to note that the native digestion method did identify proteins in both samples that the HILIC 
method did not detect. 
Overall, the HILIC method resulted in more sensitive detection and more positive 
identifications, but it is important to consider lack of overlap in identifications. The heat 
precipitation step in the native digestion method is a potential cause of HCP loss as is the 
concentration step in the HILIC fractionation method due to changing buffer conditions and 
potential HCP insolubility at low volumes. These factors may lead to effective ‘blind spots’ in 
HCP characterization and limit the sensitivity of their respective methods. This result suggests 
that the two methods should be used together to obtain a more complete overall profile of HCP 
content in more complex Ab samples. However, our HILIC fractionation method is a practical 
option for non-Ab type species.  
3.3.3. Absolute Quantitation of HCPs in Therapeutic Abs with “Hi-3” method 
 While residual HCP identifications are useful, regulatory standards require reporting the 
total concentration of HCPs in a DS [31-33]. With sensitive assays, such as ELISA, offering high 
parallelizability and quantitative analysis, a competitive LC-MS method needs to provide not 
only identification lists of detectable HCPs but quantitative measurements of each identified 
protein as well. The “Hi-3” method [34] can be used to approximate the concentration of proteins 
in a sample taking the top three most ionizable peptides from each positive HCP identification 
and calculating their molar abundance based on the top three ionizing peptides from a spiked 
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internal standard at a known molar concentration. The concentrations can then be converted to 
ppm values (ng HCP/ mg therapeutic protein) for reporting. Quantifiable proteins were selected 
by including more stringent filtering conditions than the previous identification lists including a 
minimum of three unique peptides per protein in order to confidently use the “Hi-3” quantitation 
method. Also, a minimum peptide length of six amino acids was required to avoid grouping 
short, conserved sequences to multiple proteins or measuring the additive signal of a conserved 
sequence from multiple proteins, both of which contribute to artificially inflated abundances.  
We quantified the HCP content in both BMS mAb 2 and NIST mAb with both methods 
and compared the HILIC fractionation method to the native digestion method. Unsurprisingly, 
proteins that were identified and quantified in both BMS mAb 2 and NIST mAb were 
consistently measured in higher concentrations by the HILIC fractionation method which 
approximated 1828  ± 1003 ppm HCP concentration in  NIST mAb compared to 575 ± 49 ppm 
HCP approximated by the native digestion method. Not only was the overall total concentration 
measured to be higher with HILIC fractionation, but almost every identified protein was 
individually measured at higher concentrations as well.  
One of the HCP identifications in our NIST mAb analysis led us to question the validity 
of our absolute concentrations because the presence of clusterin was detected by both methods in 
two out of the three replicates. Clusterin was measured to be near 100 ppm which made it one of 
the most abundant HCPs identified in the samples, which is unusual as clusterin has not been 
previously characterized in NIST mAb. At such a high abundance level, even less sensitive 
methods should have identified this protein if it was a true contaminant. Potential sample 
contamination issues may have led to this identification, and therefore, we chose not to publish 
our identification lists until further validation experiments could be carried out. Additionally, the 
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presence of exogenous contaminants precluded comparing our results to the published HCP 
concentrations [30] measured by ELISA, however, we can accurately compare our results 
between our methods as both analyses were carried out on the same stock samples. 
The under approximation observed with the native digestion method may be explained by 
poor digestion efficiency of proteins in their native folded conditions which lowers the overall 
rate of digestion. This condition may have the effect of lowering the average ion signal of each 
peptide in the MS analysis and result in underestimation of protein concentrations. From these 
data, we can further surmise that the HILIC fractionation method is not only more sensitive, but 
potentially more accurate than the native digestion method. However, the precision and 
reproducibility of the measurements will need to be improved before such conclusions can be 
confidently asserted.  
One of the current drawbacks to peptide quantitation with Progenesis QI, is the 
propensity for proteins to have conserved tryptic peptide sequences. The software assigns these 
peptides to each protein, causing high abundance peptides from one protein to also be attributed 
to other low abundance proteins. This artifact potentially results in overestimation of the 
individual concentrations of these low abundance peptides. Resolving these conflicts is carried 
out manually and for each conflicting peptide adds significant time to the analysis. The BMS 
mAb 2 sample had over 400 quantifiable proteins with hundreds of peptide conflicts that needed 
manual resolution. Our approach to improve the feasibility of this analysis was to filter for a list 
of known ‘problem HCPs’ that have been documented in drug development as commonly 
characterized impurities that are problematic in drug formulations. Included in this list are 
proteases that degrade protein stability, lipases that degrade the stabilizers in the drug 
formulations, and potential effectors of immunogenicity in drug administered patients.  
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We compiled the results (Table 3.5) and compared both LC-MS methods. Six ‘problem 
HCPs’ were identified in BMS mAb 2 by the HILIC fractionation method while only four of 
those proteins were identified by the native digestion method. Again, it appears that our HILIC 
fractionation method outperforms the native digestion method with a more sensitive protein 
analysis. Similar to what we observed in our NIST mAb quantitative analysis, the HILIC method 
also measured higher concentrations of each peptide with lipoprotein lipase and 
carboxypeptidase (Table 3.5) both calculated to have about 10-fold higher ppm values than the 
native digestion method, and the lowest concentration measured by the method reached 0.6 ± 
0.5ppm. These results indicate that our method lowers the detection limit approximately 10-fold 
compared to any other LC-MS method to date.  
Overall, the results indicate that our HILIC fractionation method is a highly sensitive 
platform for HCP detection and absolute quantification in purified DS, and using this method we 
effectively lowered the limit of quantitation (LOQ) an order of magnitude. The native digestion 
method, on the other hand, offers a robust and technically simple protocol for HCP 
identification, but it lacks the ability to characterize non-Ab samples. When comprehensive HCP 
profiling in Ab samples is necessary, both methods can be used in conjunction to significantly 
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increase the number of positive identifications for Ab-type samples, however, when absolute 
quantitation is necessary, our method outperforms other LC-MS techniques.  
3.3.4. Improving the Native Digestion of Therapeutic Antibodies for HCP Characterization 
 The native digestion protocol offers a practical and elegant solution to Ab depletion in 
HCP analysis. However, the previous evaluations indicate significant limitations with this 
method in detection sensitivity and accuracy of the absolute protein concentration measurements. 
We believe the observed underperformance may be a result of poor digestion efficiency, 
lowering the overall quantity of peptides available for ionization and we therefore sought to 
evaluate different digestion conditions to improve overall efficiency and potentially increase the 
detection sensitivity and quantitative accuracy of the method.   
The Ab depletion mechanism underlying the native digestion method, presented by 
Huang et al. [13], is based on the slower kinetics of Ab digestion under native folded conditions. 
In their protocol, they forego the use of reducing and chaotropic reagents that disrupt native 
protein structures.  However, this approach was observed to lower the total HCP peptide 
concentrations in our samples as HCPs may be similarly difficult for trypsin to digest under 
native conditions. Therefore, we explored the effects of adding reagents such as dithiothreitol 
(DTT) and urea to the samples prior to digestion. We hypothesized that by disrupting some of 
the native folding, but not all, we would see some improvement in digestion efficiency without 
sacrificing sensitivity by over-digesting the abundant therapeutic protein.  
Replicate samples of NIST Ab and BMS mAb 2 were analyzed according to the Huang et 
al. protocol, however, in our experiments, they were digested overnight in buffers containing 
either 3.25 mM DTT, 2.0 M Urea, or a combination of both. These variables respectively 
represent reducing conditions, denaturing conditions, or both. Total HCP counts of all unique 
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proteins identified between replicates were compiled and compared across conditions (Figures 
3.8 and 3.9). In contrast to the analysis in Table 3.4, compiling all unique proteins identified in 
our replicates effectively increased the total number of unique identifications made by the native 
digestion method compared to averaging the results.  
Averaging total HCP counts between replicates helps indicate the robustness of our 
methods, however since the robustness of the native digestion protocol is well documented, 
adding all positive identifications in each replicate and removing duplicate identifications 
provides a more comprehensive profile of HCP content in our samples. Although, while this 
approach can provide an improved assessment of the sensitivity of the method, certain proteins 
that scored near our lower confidence threshold and that were identified in only one or two of the 
replicates, required further validation to ensure these hits are not false positives.  
 
 
Figure 3.9. Average total HCPs identified in NIST Ab using the native digestion 
protocol with 2.0 M urea, 3.25 mM DTT, or a combination of both in the digest 
buffer. Green tiles indicate statistical significance (p < 0.05). 
NIST mAb Native Digestion HCP count
DTT
n = 3
Urea 
-
+
60 81
46 47
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Between the two experiments, only the (+) DTT condition in our NIST mAb sample 
showed a statistically significant increase in the number of HCPs identified, indicated by the 
green tile (Figure 3.10). This result is most likely due to the reduction of disulfide bonds 
allowing for more efficient digestion of the HCPs, but validation experiments are needed to 
verify these results. The BMS mAb 2 sample, on the other hand, was unaffected by the additions. 
In all three replicates the urea-containing samples showed slightly more hits, but additional 
experiments will be necessary to reach statistically relevant conclusions. Since urea acts as a 
denaturant during digestion, the antibody should unfold and produce more proteolytic peptides 
which increases the overall background and reduces the detection sensitivity for low abundant 
peptides that may coelute.  
The lack of variation between conditions indicated by our results was unexpected and 
challenges the underlying hypothesis proposed by Huang et. al which rationalizes native 
structural differences between Ab and HCPs underlying the slower Ab digestion kinetics 
compared to other proteins. If the tightly folded native structure is the driver of this phenomenon 
then the addition of urea, as a denaturing reagent, and DTT, as a reducing agent, should have 
Figure 3.10. Average total HCPs identified in BMS mAb 2 using the native digestion 
protocol with 2.0 M urea, 3.25 mM DTT, or a combination of both in the digest buffer. Green 
tiles indicate statistical significance (p < 0.05). 
BMS-mAb 2  Native Digestion HCP count
n = 3
+ 371 374
DTT 
- +
Urea 
- 362 350
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disrupted the native structure of the mAb species, thereby significantly increasing the number of 
observed mAb peptides. This increase should have the effect of increasing ion suppression of 
HCP peptides as well as background noise, and should have limited the detection of the HCPs in 
the samples. Instead, we saw little change in the detection limits in the denatured and reduced 
samples. In fact, the reduction of NIST mAb samples increased the number of HCPs identified, 
and the addition of both reagents to the BMS mAb 2 sample slightly increased the number of 
HCP identifications in our analysis. While further work needs to be performed to compare the 
overlap of identified peptides between conditions to validate our results, the lack of significant 
change between conditions was unexpected and potentially contradicts the proposed HCP 
enrichment mechanism. It is possible that the lack of heat and relatively low urea concentration 
(2.0 M) was insufficient to denature the tightly folded mAbs, and addition of DTT, which 
reduces disulfide bonds, may have improved HCP digestion in the NIST mAb sample while still 
leaving the heavy and light chains of the mAbs tightly wound and difficult to digest. Overall, 
denaturing and reducing conditions either significantly improved or had little effect on the 
detection sensitivity of the native digestion method. This approach may allow for more accurate 
estimates of protein concentrations. Therefore, the logical next step would be to quantify the 
identified peptides and evaluate the HCP concentration estimates. Our efforts have shown that 
native digestion conditions are not necessary for HCP peptide enrichment, and they have opened 
further questions about the underlying enrichment mechanism of the Huang et al. method. 
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Chapter 4 
 
 
Conclusions and Future Directions 
 
   
   
 Liquid chromatography-mass spectrometry (LC-MS) remains an essential tool in 
biomedical research. The work described in this dissertation centers around leveraging this tool 
to develop ‘bottom-up’ LC-MS strategies for enhanced detection of labile, non-antigenic post-
translational modifications (PTM) and trace protein impurities in biotherapeutic drug substances.  
4.1 Direct Identification and Site-Specific Analysis of S- Palmitoylation  
The strategies employed in the work described in Chapter 2 evaluated and optimized a liquid 
chromatography-mass spectrometry (LC-MS) based analytical workflow for the direct detection 
of S-palmitoylated peptides in complex mixtures. Our work defines sample preparation, 
chromatographic separation, and MS analysis considerations to limit the loss of labile 
palmitoylation from cell lyses through LC separation and MS/MS fragmentation (Figure 4.1).  
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 Each of these steps and conditions were evaluated and optimized to prevent hydrolysis of 
the S-palmitoyl thioester bond and to maintain the solubility of lipidated or otherwise 
hydrophobic peptides in sample solutions so that they can be analyzed by LC-MS. Figure 4.1 
presents important conditions that should be considered by future researchers seeking to analyze 
S-palmitoylation with ‘bottom-up’ LC-MS/MS workflows. As proof of concept, we applied 
these method considerations and achieved the novel, direct detection of recombinant N-Ras 
palmitoylation in a complex mixture.  
 As the importance of the regulation of S-palmitoylation is continually realized, directly 
detecting these labile modifications in large scale studies of palmitoylated protein populations by 
tandem MS will be an available option. Future studies should expand on the foundation built in 
this work and seek to further optimize the workflow conditions and parameters to globally 
profile lipidation in a proteome. Several challenges can be expected when transitioning to 
proteome wide studies such as the low abundance of this PTM in most tissues. Generally, 
enrichment techniques are used to reduce background interference during analysis and to 
increase signal of low abundant species. New strategies will need to be employed to overcome 
this challenge while taking into consideration the labile and non-antigenic nature of this PTM. 
Our strategy was to leverage the hydrophobicity of the greasy acyl-chain and modify our 
chromatography to, in effect, wash the more hydrophilic background away. While this strategy 
works for single peptide analyses, analyses requiring high sequence coverage of proteins of 
interest and proteome-wide studies will need to develop additional strategies to improve 
signal/noise ratios for low abundance palmitoylated peptides in complex mixtures.  
 LC-MS/MS analyses of mouse brain tissues, which are known to contain higher levels of 
palmitoylation than other tissues, should be considered when studying dynamic palmitoylation 
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conditions or to directly detect novel sites of palmitoylation. Additionally, our workflow can 
serve as an outline for validating reported palmitoylation sites catalogued by the SwissPalm 
database with direct LC-MS analysis. Similarly, elements of the workflow strategies detailed in 
Chapter 2, such as using C-8 chromatography, may be used in future studies of the hydrophobic 
proteome which may advance our understanding of membrane protein dynamics, interactions, 
and structure. 
 The labile nature of palmitoylation will remain a challenge in direct detection of 
palmitoylation sites. Electron transfer dissociation (ETD) provided the highest sequence 
coverage for palmitoylated peptides with minimum neutral palmitate loss and, therefore, should 
be considered in future analyses. As instrumentation capable of ETD become more readily 
available, methodologies utilizing this technology may become more practical for general 
research purposes, however limitations do exist which must be overcome. Importantly, ETD 
adds a negative charge to precursor ions and therefore requires high charge states for peptides of 
interest. This charge state requirement can be a problem for complex samples where matrix 
analytes compete for charge during electrospray ionization (ESI) or for lipidated peptides which 
tend to exhibit poor ionization efficiency. One strategy that should be explored is post-column 
introduction of supercharging reagents to effectively increase the average charge of peptide ions 
and thus increase the effectiveness of ETD fragmentation. This strategy could provide an 
effective alternative to our HCD step-fragmentation method, detailed in Chapter 2, and increase 
global palmitoylated peptide fragmentation coverage. Overall, this work provides a foundation 
for directly detecting S-palmitoylated peptides and serves to explore orthogonal strategies to 
conventional indirect detection methods. 
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4.2 Improving Detection Sensitivity for Host-Cell Protein Characterization  
 The offline fractionation method and plate-based workflow, described in Chapter 3, 
serves as a sensitive LC-MS-based host cell protein (HCP) characterization platform. This 
platform can serve to support downstream analysis of HCP content in drug substances (DS) 
across multiple biotherapeutic protein classes. Furthermore, our proposed workflow limits most 
sample specific optimizations, achieves ppm level sensitivity for HCP detection and absolute 
measurements of residual HCP impurities. Our modifications of the Wang et al. method included 
implementation of automated fraction collection and a single-plate sample processing workflow 
that reduces HCP loss from multiple vial transfer steps and significantly reduces parameter 
optimization time required between samples, thereby improving the feasibility of this method for 
adoption in industrial process development. Additionally, our plate-based method improves 
processing throughput where up to 16 samples can be fractionated in sequentially for multiple 
sample analyses. Figure 4.2 presents a diagram outlining our proposed workflow for HCP 
characterization for use in downstream critical quality attribute analysis of biotherapeutic drug 
substances. 
 Although our method reliably measured higher concentrations of HCPs when compared 
to other LC-MS strategies, our method did not provide the robustness between runs that would 
be expected of a standardized workflow. Future experiments will need to be carried out to 
determine the root cause of variance between replicates in both the HILIC and native digestion 
methods. Future work should also examine the properties of specific HCPs detected by different 
methods/conditions to elucidate why some HCPs are poorly recovered by one method as 
opposed to the other, and compare HCP identifications between replicates to determine the 
reproducibility of each unique identification. Such experiments will serve to justify the use of 
one method over another comparable method and potentially explain causes underlying the 
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discrepancies between runs. Furthermore, it is important to note that our work failed to provide a 
benchmark for evaluating the absolute quantitative accuracy of each LC-MS method, and by 
comparing each method’s HCP measurements with those of an ELISA will help support our 
method’s quantitative accuracy and could potentially validate our results. Another 
complementary approach for validating our method’s quantitative accuracy would be to measure 
the levels of multiple spiked proteins at known concentrations. Such experiments would help 
identify, with improved precision, the accuracy of our results.  
 Dynamic range is an important consideration when using ESI based ionization for LC-
MS analyses and will continue to be problematic as higher purities of biotherapeutic proteins are 
achieved. Methods such as 2D-chromatogprahy and sample fractionation allow for separation of 
the trace impurities from the drug substance and improve the dynamic range of detection. 
However, certain limitations with these strategies exist, including the increased analysis time 
and, consequentially, lower throughput compared to other existing bioanalytical methods. Our 
workflow sought to mitigate these issues, specific to LC-MS analysis strategies but is still 
incapable of the level of parallelizability inherent with other bioanalytical techniques, such as the 
Enzyme-linked Immunosorbent assay (ELISA).  Future work should seek to improve this 
workflow to further increase throughput and reduce analytical workload. A higher degree of 
automation, such as implementing software for fraction collection that automatically detects UV 
chromatographic peak formation during fraction collection instead of manually optimizing time-
based fraction window parameters, could drastically improve throughput. Additionally, enhanced 
automation would eliminate sample specific optimization still needed in our HILIC fractionation 
step and serve to further generalize the application of this method as a platform for HCP 
characterization. 
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Future advancements will undoubtedly turn towards improving the limits of detection and 
quantitation to the ppb concentration range and will most likely require concentrating larger 
quantities of HCPs during the fractionation step. To achieve this goal, using a larger diameter 
HILIC column, such as a 4.6 mm inner diameter (ID) column compared to the 2.1 mm ID 
column employed in Chapter 3, will be necessary for larger volume injections.  
 While identifying and quantifying HCPs in biotherapeutics is demonstrably important, 
efforts are currently underway to improve the downstream purification process to further deplete 
these HCPs from the drug substance and thereby improving the overall purity of biologics 
products. LC-MS analysis can aid this endeavor, and again demonstrate the analytical 
capabilities exclusive to mass spectrometry, by identifying and characterizing specific proteins 
that evade purification. Identifying the HCPs that are consistently and reproducibly present 
between samples may help elucidate the underlying cause of HCP contamination and provide 
helpful information for process development in biotherapeutic manufacturing. 
LC-MS based protein analysis will remain an essential tool in protein analysis for years to 
come. As computational algorithms and instrumentation evolve to match current analytical 
demands, novel strategies will need to be developed to fully capitalize on the detection 
capabilities and the analytical power inherent in this technique. Our methods add to the 
repertoire of analytical capabilities that LC-MS systems provide, and further illustrate the power 
of this technique for protein analysis. By applying the concepts and considerations outlined in 
the preceding chapters, new challenges can be addressed that will definitively advance the field 
of LC-MS based protein analysis.  
